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To my offspring
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CHAPTER 1. SHORT SUMMARY
1. Short summary
Although the oral route is preferred for drug administration due to its convenience for the
patient, many new chemical entities suffer from low oral bioavailability due to poor aque-
ous solubility. Especially for BCS class II drugs, overcoming the limited solubility is crucial
for a successful therapy. A relatively new technique in this context is the use of hot melt
extrusion for the production of fast dissolving solid solutions.
This thesis focuses on the novel excipient Soluplus R, combining solubilization and the
ability to form solid solutions by hot melt extrusion in one molecule. The potency of dif-
ferent formulations to improve the bioavailability of BCS class II drugs was evaluated in
the Caco-2 cell culture model. An excellent correlation between in vitro transport across
cells and in vivo studies in dogs was found.
As many solubilizers can modulate active transporters, Soluplus R was tested in Caco-2
cells for a possible interaction with the P-glycoprotein efϐlux system. An efϐlux inhibition
by Soluplus R at comparably high effective concentrations was found. Uptake studies in
MDCK II cells validated these results.
Furthermore, themechanismof interactionbetweenSoluplus R andmodel drugswas stud-
ied, allowing theoptimizationof formulationswith regards todrug/excipient ratios. There
is a window of ratios with maximal transport rates across Caco-2 cells, as result of an in-
terplay between solubilization, binding of drug to Soluplus R and the amorphous state of
the drugs.
V

KAPITEL 2. KURZZUSAMMENFASSUNG
2. Kurzzusammenfassung
Die beliebtesten Arzneiformen sind die zur oralen Gabe. Viele neue Arzneistoffe besitzen
allerdings eine geringe orale Bioverfügbarkeit auf Grund ihrer schlechten Wasserlöslich-
keit. Insbesondere für BCS Klasse II Substanzen ist die geringe Löslichkeit die entschei-
dende Hürde für eine erfolgreiche Therapie. Eine neue Technik zur Überwindung dieser
Hürde ist die Schmelzextrusion zur Herstellung schnellauϐlösender fester Lösungen.
In dieser Arbeit wurde der neuartige Hilfsstoff Soluplus R untersucht, welcher Löslich-
keitsverbesserung und die Möglichkeit zur Herstellung fester Lösungen durch Schmelzex-
trusion in einem Molekül vereinigt. Die Wirksamkeit von Formulierungen mit Soluplus R
wurde im Caco-2 Zellkulturmodell beurteilt. Eine sehr gute Korrelation ergab sich zwi-
schen dem Arzneistofftransport über Caco-2-Zellen und in vivo Studien an Beaglen.
Da viele Solubilizer den Efϐluxtransporter P-Glykoprotein modulieren, wurde Soluplus R
auf eine solche Interaktion getestet. An Caco-2 undMDCK-II Zellen konnte eine P-gp-Hem-
mung bei hoher Soluplus R-Konzentration gezeigt werden.
Zusätzlichwurdedie Interaktion zwischenSoluplus R undModellarzneistoffenuntersucht.
Hierbei wurden Formulierungen hinsichtlich des Verhältnisses zwischen Arzneistoff und
Hilfsstoff optimiert. Ein Optimum für maximalen Arzneistofftransport konnte an Caco-2-
Zellen gezeigtwerden,welches sich aus demZusammenspiel von Solubilisierung, Bindung
des Arzneistoffs zu Soluplus R und der Amorphizität des Arzneistoffs ergibt.
VII

CHAPTER 3. GENERAL INTRODUCTION
3. General Introduction
3.1. Liberation and absorption of drugs after oral application
The action of drugs is steered by the two partners pharmacokinetics and pharmacody-
namics. While pharmacodynamics is mainly dependent on the active pharmaceutical in-
gredient (API), for pharmacokinetics the dosage form also plays an important role. Phar-
macokinetics is often described by the LADME scheme which summarizes the processes
of pharmacokinetics:
 Liberation from the dosage form
 Absorption into the blood circulation
 Distribution of the drug in ϐluids and tissues
 Metabolism of the compound
 Excretion or elimination of the drug from the body
For oral application, the steps of liberation and absorption of a drug are essential for a
successful therapy. Oral dosage forms are the most frequently used and favored formula-
tions: At least 40% of all APIs are applied as tablets [1]. Therefore, the development and
optimization of these dosage forms is one of the main aspects of pharmaceutical technol-
ogy.
The liberation of the API from its formulation is a complex process, including a number
of simultaneous subprocesses such as wetting, disintegration, swelling, diffusion and dis-
solution [2]. All of these subprocesses may be targeted and controlled in formulation of
an API, resulting in diverse coatings, sustained release formulations, rapidly disintegrat-
ing dosage forms and so on. However, the solubility of an API itself in the intestinal ϐluids
1
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is the limiting factor for the liberation of many drugs. Especially for lipophilic APIs, their
characteristically poor aqueous solubility is the biggest hurdle for a successful oral appli-
cation.
3.1.1. Drug solubility and dissolution
The aqueous solubility of an API is mainly dependent on its chemical structure. Hydro-
philic, polar APIs provide a good solubility, while lipophilic, nonpolar substances show a
poor aqueous solubility. Therefore it is clear, that drug solubility may be improved in an
early state of drug development by the synthesis of water-soluble salt forms or prodrugs.
Drug dissolution is generally described by the equation of Noyes and Whitney [3]:
dc
dt
=
AD  (cs   ct)
V  h (3.1)
whereas dcdt represents the rate of dissolution, A the surface area, D the diffusion coefϐi-
cient, cs the saturation solubility of the compound in the dissolution medium, ct the con-
centration of the compound at time t, V the volume of the dissolution medium and h the
thickness of the diffusion layer around the surface of the solid compound. Following this
equation, one main possibility to increase the dissolution rate is an increase of the sur-
face A. Obviously, the surface area of a drug powder is strictly dependent on the size of
each particle. Size reduction (and hence an increased surface area)may be realized bymi-
cronization through milling processes. Micronized particles provide a large surface area
and therefore also a better wettability, which may also be enhanced by addition of sur-
factants. A maximal surface area of the solid compound may be realized if it is applied
in amorphous state or molecularly dispersed in a solid form (see Chapter 3.3). Another
approach to increase the dissolution rate is the increase of the apparent solubility cs by
addition of solubility enhancers (e.g. micelle forming surfactants; see Chapter 3.2).
Furthermore the temperature of the solvent triggers the aqueous solubility, depending on
the enthalpy change of a solution. If the dissolution process is exothermic, the solubility
decreases by increasing temperature and vice versa for an endothermic process [1]. As for
2
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Stomach pH <3
Anus
Appendix
Cecum
Colon pH 5
Rectum
Duodenum pH 4.9-6.5
Jejunum pH 4.4 - 6.5
Ileum pH 6.5 - 8.0
Figure 3.1.: The gastrointestinal tract and corresponding pH values (according to [4]; Pic-
ture: public domain)
all mammals the body temperature is equilibrated to about 37 C, this fact does not play
an important role in the formulation of oral dosage forms.
Even more important regarding API solubility is the composition of the gastro-intestinal
ϐluids. First, the pH of the solvent is crucial for the solubility of APIs, which are present as
salts, weak bases or acids. Such compounds undergo protonation and deprotonation and
therefore changes in their polarity. The pH of the intestinal ϐluids is mainly dependent on
the section of the GI-tract (Figure 3.1). The stomach provides acidic conditions, through
the secretion of hydrochloric acid [5]. The intestinal pH gradually increases, caused by se-
cretion of bicarbonate from the pancreas. Through GI-passage the pH rises from around 5
in the duodenum up to 7–8 in the terminal ileum [4]. Finally, in the colon the pH slightly
decreases, as undigested carbohydrates aremetabolized to short chain fatty acids [6]. Fur-
thermore, the pH is dependent on food intake. In fed state the gastric pH rises to values
between 3 and 7, while intestinal pH stays approximately constant [4].
Second, the intestinal ϐluids contain bile salts and lecithin. These two components are able
to formmixed micelles, which may solubilize APIs. The amount of bile salts is strongly in-
creased within thirty minutes after ingestion and decreases 120–150 minutes reverting
back to the pre-prandial level. However, also at fasted state mixed micelles are present in
3
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Class I Class II
High solubility Low solubility
High permeability High permeability
Class III Class IV
High solubility Low solubility
Low permeability Low permeability
Table 3.1.: The Biopharmaceutics Classiϐication System (BCS), according to [7]
the intestine [4].
GordonAmidon et al. introduced theBiopharmaceutics Classiϐication System (BCS),which
classiϐies APIs upon their solubility and their intestinal permeability ([7], Table 3.1). This
system is established andacceptedby theUSFoodandDrugAdministration (FDA) as guide
for the prediction of drug absorption after oral intake. The FDA consideres a drug as highly
solublewhen the highest dose strength is soluble in 250ml or less of aqueous media over
the pH range of 1–7.5 [8]. A drug is considered as highly permeable if 90% or more of
an orally applied dose is absorbed in humans [8]. This usually correlates to an apparent
permeability of 10 10 6 cm/s in Caco-2 transport experiments. According to this sys-
tem, the intestinal absorption of lipophilic drugs with a high intestinal permeability (BCS
class II) can be predicted by in vitro dissolution experiments [9]. Although the standard
pharmacopoeia dissolutionmethods provide good in-vitro-in-vivo correlations (IVIVC), an
even better correlation between in vitro and in vivo data for BCS class II substance can be
reached by the use of more biorelevant dissolutionmedia such as simulated intestinal ϐlu-
ids. Since for BCS class II substances the drug dissolution is the most important step for
successful intestinal absorption, the use of solubilizing agents is accordingly a promising
way to increase the oral bioavailability of poorly aqueous soluble drugs.
3.1.2. Principles of drug absorption across the intestinal mucosa
The intestinal mucosa is the most important barrier for drug absorption after oral appli-
cation. As the small intestine provides a large area of 180 m2, it is the main organ for
the absorption of nutrients and also xenobiotics [5]. As described by the BCS, the per-
4
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Luminal side
Blood side
ATP    ADP ATP    ADP
ATP    ADP
Tight junction }}Apical sideBasolateral side
A B C D E F G H
Figure 3.2.: Pathways for transport across the intestinal epithelium: A Transcellular pas-
sive diffusion B Paracellular passive diffusion C Facilitated transport D Ac-
tive inϐlux under ATP consumption EActive efϐlux under ATP consumption F
Vesicular transport after apical endocytosis (transcytosis) G Basolateral ac-
tive transport (efϐlux or inϐlux) H Passive diffusion with additional enzymatic
metabolism
meability of a certain drug through the intestinal barrier is as well important for its oral
bioavailability. There are several ways for a drug to pass the intestinal epithelium as de-
scribed in Figure 3.2. The transcellular and the paracellular pathway (Figure 3.2 A & B)
are passive processes, following a concentration gradient. Both ways are dependent on
the physicochemical parameters of the API. The limitations of transcellular diffusion are
described by “Lipinski’s Rule of 5” [10]. According to this, a high permeability is likely for
molecules that provide at least three of the criteria:
1. Maximal 5 H-bond donors
2. Maximal 10 H-bond acceptors
3. A molecular mass less than 500 Da
4. A logP lower than 5
Paracellular transport is described as diffusion in between the cells, passing the inter-
connecting tight junctions through pores. These pores were found to have a diameter
of 0.5–5 nm. Therefore, the size of molecules transported by this way should not extent
300Da [11]. Furthermore, paracellular diffusion is preferred by hydrophilic compounds,
since these compounds hardly diffuse into the lipophilic cell membrane, which is essential
for transcellular transport.
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Besides passive diffusion through or between the cells, transporter proteins may affect
the intestinal absorption. These proteins permit the absorption of compounds, which are
excluded from transcellular or paracellular diffusion, e.g. due to their physicochemical pa-
rameters. Facilitated transport (Figure 3.2 C) enables the diffusion of a certain substrate,
but is still driven by a concentration gradient. Facilitated transport is described for very
polar molecules, such as amino acids or glucose. In contrast, active transport can take
place against a concentration gradient under consumption of energy. It is described for
both possible directions (Figure 3.2 D & E): from the blood to the luminal side (efϐlux)
and from the luminal side to the blood (inϐlux).
Active efϐlux in the intestinal mucosa generally leads to a reduced bioavailability of sub-
strates of such active transporter proteins. Additionally, efϐlux transporters are a possible
site of drug-drug or drug-excipient interactions. Inhibition or induction of those proteins
may lead to a changed relative bioavailability and hence results either in increased toxicity
and side effects or in a reduced activity of a certain drug [12].
The big majority of human efϐlux transporters belong to the ATP binding cassette (ABC)
superfamily, a class of proteins that is ubiquitarily expressed [13]. This large group of pro-
teins is characterized by the sequence and organization of their ATP binding sites. This so
called nucleotide binding folds (NBFs) consist of speciϐic motifs: Walker A and B, which
are separated by 90–120 amino acids and a signature C motif, upstream of the Walker B
motif [14]. To establish an efϐlux, also against a concentration gradient, energy is needed.
As for many biological processes the hydrolysis of ATP to ADP is used as energy source,
releasing around 30 kJ/mol of free energy. The physiological function of these efϐlux trans-
porters is mainly to protect the human body from potentially toxic substances, including
xenobiotics and also physiological metabolites [15, 13]. ATP transporters are the main
cause for the phenomenon of multidrug resistance in cancer therapy [16, 17]. Especially
the transporter proteins P-glycoprotein, multidrug resistance associated proteins (MRPs)
and the breast cancer resistance protein (BCRP) were identiϐied to be overexpressed in
tumor cells and to efϐlux cytostatic drugs from tumors [16, 18].
6
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Figure 3.3.: X-ray structure of P-gp. Yellow: N-terminal half of the protein. Blue: C-
terminal half of the protein. Transmembraneous (TM) and nucleotide binding
domains (NBD) are labeled. The horizontal bars represent the position of the
cell membrane. Adopted from [21]
Active efϐlux by human P-glycoprotein
P-glycoprotein is often considered as the most important human efϐlux protein. The ex-
istence of this protein was ϐirstly proven in mutant chinese hamster ovary (CHO) cells,
showing a resistance towards colchicine [19]. Human P-glycoprotein is coded by the gene
MDR1on chromosome21which is also known as ATP-binding cassette sub-family Bmem-
ber 1 gene (ABCB1). However, P-gp, MDR1 or ABCB1 are often used as synonyms for the
transporter protein. It is a transmembraneous protein of 170 kDa with two halves of six
transmembraneous domains each [13, 20]. Each half wears an intracellular ATP-binding
site (nucleotide binding domain (NBD)). The active transport is established by the energy
from the enzymatic hydrolysis of ATP. The transport is commonly explained by the so-
called hydrophobic vacuum cleaner hypothesis. According to thismodel, the substrate par-
titions into the lipid bilayer and enters the drug binding site of the protein through an open
portal [21]. When ATP then binds to the NBDs, a conformational change of the protein is
performed and the substrate is presented to the extracellular space (Figure 3.4).
Apart from overexpression of P-gp in multidrug resistant tumors, P-gp plays an important
physiological role at several barriers of the human body [22]. In general, P-gp transport is
7
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Figure 3.4.: Substrate efϐluxbyP-gp: Substrate (magenta) diffuses into the lipidbilayer and
enters P-gp to the drug binding site (cyan). After binding of ATP to the NBDs,
conformational changes lead to the unidirectional substrate efϐlux. Adopted
from [21]
directed towards the elimination routes from the human body. For example, it mediates
the transport from the intestinal mucosa cells into the lumen, in the kidneys into the uri-
nary system or at the blood-brain barrier in direction of the blood [23, 24]. Accordingly,
P-glycoprotein activitymay reduce the oral bioavailability of certain drugs [25]. Inhibition
or induction of P-gp therefore may lead to increased or reduced bioavailability, respec-
tively. The group of drugs and natural products which are known to affect the function of
P-gp is not much smaller than the group of substrates. An overview of substances known
to be substrate, inhibitor or inducer of P-gp is given in Table 3.2. Substrates of P-gp are
usually of hydrophobic nature and do not extent the size of 2000 Da.
As result of this broad range of substrates, P-gp is prone to drug-drug and also drug-
excipient interactions [27, 28]. Especially the combination of P-gp inhibitors with drugs
providing a low therapeutic index is known to result in increased toxicity, e.g. azol-fungi-
cides + digoxin. A reduced bioavailability of drugs is described for the interactions be-
tween P-gp inducers, such as St. John’s wort ϐlavonoids and P-gp substrates, for example
oral contraceptives or anticoagulants [26]. P-gp inhibition has not only been described for
drugs and herbal products, but also for many excipients. Especially for non-ionic surfac-
tants, P-gp inhibition could be shown but also for other natural and synthetic polymers
8
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Substrates Inducers Inhibitors
-blockers: Dexamethasone Antiarrythmics:
carvedilol, celiprolol, talinolol doxorubicin amiodaron, chinidin, lidocain
Calcium channel blockers: ϐlavonoids (quercetin, Antimycotics
diltiazem, nicardipine, verapamil kaempferol) itraconazole, ketoconazole
H1-blockers: St. John’s wort Calcium channel blockers:
fexofenadine, terfenadine phenobarbital diltiazem, felodipine,
HIV protease inhibitors: phenytoin nicarpidine, nifedipine,
indinavir, nelϐinavir, ritonavir, rifampicin nitrendipine, verapamil
Steroids: vinblastine HIV protease inhibitors:
endogenous steroid hormones, indinavir, nelϐinavir, ritonavir,
dexamethasone saquinavir
Immunosuppressants: Steroids:
cyclosporine, sirolimus, tacrolimus ethinylestradiol, norgestrel,
Cytostatics: progesterone, testosterone
doxorubicin, etoposid, mitomycin, Immunosuppressants:
mitoxantron, paclitaxel, teniposid, cyclosporine, tacrolimus
vinca alkaloids Antibiotics:
Other: clarithromycin, erythromycin
chlorpromazine, colchicine, digoxin, Other:
furosemide, loperamid, methadon, mifepriston, paroxetin,
midazolam, phenytoin, quetiapin, talinolol, vincristine
rifampicin, simvastatin
Table 3.2.: Substrates, inducers and inhibitors of P-glycoprotein. Adopted from [26]
[29, 30, 31]. A summary of excipients which are known to have a P-gp inhibitory potential
is given in Table 3.3. Besides unwanted interactions between P-gp inhibitors and sub-
strates, the interaction may also be desired in the case of poorly bioavailable drugs. The
combination of the inhibitor (& solubilizer) Vitamin E TPGS 1000 and the HIV-1 protease
inhibitor amprenavir was commercialized under the trade name Agenerase R oral solu-
tion [32]. However, this drug was replaced by the pro-drug fosamprenavir calcium salt
(Telzir R/Lexiva R) which provides a higher aqueous solubility [33]. Also in cancer ther-
apy the combination of drug and P-gp inhibiting excipientwas used to circumvent themul-
tidrug resistance phenomenon, for example by the use of Cremophor EL [34, 35]. Due to
this high potential of possible wanted or unwanted interactions it is clear that a novel sol-
ubilizing non-ionic excipient,such as Soluplus R, is suspected to be a potential inhibitor of
P-gp.
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Excipient Effective concentration [%]
Xanthan gum 0.05
Gellan gum 0.05
Flavicam 0.05
Dextran 0.05–0.1
PEG 300 20
PEG 400, 2000, 20000 0.1–20
TPGS 1000 0.0038
TPGS 200–6000 0.005
Tween 80 <0.13
Myrj 52 0.5
Pluronic P85 0.001–1
Table 3.3.: Excipients known for P-glycoprotein inhibition, assembled from [31]
Hydrophilic	head
(well	soluble)
Lipophilic	tail
(poorly	soluble)
SINGLE	SURFACTANT	MOLECULE MICELLE
Figure 3.5.: Principle structure and formation of micelles.
3.2. Formulation of poorly aqueous soluble drugs by micellar
solubilization
Strategies to increase the aqueous solubility of an API are the use of surfactants, co-sol-
vents, complexing agents, micronization, or special drug delivery technologies such as
nanocrystals or nanoparticles. In solution, surfactants aggregate to micelles in concen-
trations above the critical micelle concentration (CMC) forming a colloidal solution. In
an aqueous solutions the surfactant molecules in a micelle are orientated, such that their
nonpolar tails form the core and their polar heads the shell of the structure (Figure 3.5).
In surfactant concentrations below the CMC the solubility of an API is equal to its solu-
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bility in the pure solvent, e.g. an intestinal ϐluid. Above the CMC the solubility increases
linearly with the surfactant concentration, described by the general equation for micellar
solubilization:
STOT = sw +  cMIC (3.2)
where STOT is the total molar solubility of the solute, sw is the water solubility of the so-
lute,  is the molar solubilization capacity of the surfactant and cMIC is the molar concen-
tration of the micellar surfactant (i.e., the total surfactant concentration minus the CMC)
[36]. Throughout solubilization the lipophilic solubilizate (the API) is incorporated in the
core structure of the micelle, formed by its lipophilic tails [37]. The localization of an API
molecule inside a micelle is dependent on its lipophilicity: While hydrophilic molecules
are located in the outer shell formed by the hydrophilic heads, lipophilic molecules are
most likely to stay in the lipophilic core region [38]. As micelles formed by small-molecu-
lar surfactants are thermodynamically unstable and also provide comparably high CMCs
[38], polymeric micelles formed by amphiphilic co-polymers are as well candidates for
pharmaceutical applications. These polymers usually have low CMCs compared to small-
molecular surfactants which consequently leads to a higher stability upon dilution in the
biological ϐluids. The micellar structure of such polymeric micelles is dependent on the
polymer. The mechanism of micelle formation from amphiphilic di-block, tri-block, and
graft co-polymers (such as Soluplus R) is illustrated in Figure 3.6.
Due to their size and hydrophilicity micelles are not likely to pass the intestinal barrier.
However, the uptake of intact micelles by pinocytosis (Figure 3.2 F) could be shown [39].
The uptake of intactmicelles seems not to be themain criteria for increased bioavailability
through polymeric micelles. In the case of Vitamin K, it was shown that the API is released
by bile salts from themicelles and subsequently uptaken [40]. Althoughmicellesmay pass
the intestinal membrane, the most common way of intestinal absorption of micellar solu-
bilized APIs is the release from the micelle, leading to an equilibrium between free drug
molecules and those entrapped in micelles [41]. Therefore, polymeric micelles formed by
pH-dependent polymers were designed to improve the release of drugs through the in-
11
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Graft	co-polymer
Lipophilic	side-chains
Hydrophilic	backbone
Di-block	co-polymer
Hydrophilic	block Lipophilic	block
Tri-block	co-polymer
Lipophilic	blockHydrophilic	block Hydrophilic	block
Figure 3.6.: Formation of micelles from amphiphilic co-polymers, according to [38]. The
novel excipient Soluplus R is a graft co-polymer, providing a PEGbackbone and
vinylcaprolactam/vinyl acetate sidechains (Figure 3.9).
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Polymer API Trade name Formulation
Cremophor EL Cyclosporine A Gengraf Soft capsules, oral solution
Cremophor EL Lopinavir (+ ritonavir) Kaletra (Norvir) Soft gelatin capsule
Cremophor RH 40 Lopinavir + ritonavir Kaletra Oral solution
Gelucire 44/14 Fenoϐibrate Cil, Lipirex Capsules
Labrasol Piroxicam Piroϐlam Tablets
Vitamin E TPGS Amprenavir Agenerase Oral solution
Labraϐils Cyclosporine A Gengraf, Sandimmune Soft capsules, oral solution
Table 3.4.: Commercialized micellar drugs, derived from [43], Rote Liste & rxlist.com
testinal pH gradient [42]. Independent from the uptake mechanism, polymeric micelles
are an excellent option for solubilization and therefore enhanced bioavailability of poorly
soluble drugs. A broad variety of drug/excipient combinations formingpolymericmicelles
have so far been commercialized.
Among others, the following micelle-forming non-ionic surfactants were commercially
used for oral drug delivery: polyoxyl 35 castor oil (Cremophor EL), polyoxyl 40 hydro-
genated castor oil (CremophorRH40), polysorbate 20 (Tween20), polysorbate 80 (Tween
80), d--tocopherol polyethylene glycol 1000 succinate (TPGS), Solutol HS-15, sorbitan
mono-oleate (Span80), polyoxyl 40 stearate, variouspolyglycolyzedglycerides (Labraϐils),
Labrasol, Gelucire 44/14, and Softigen 767 [43]. A short overview of commercialized
products using the formation of micelles is given in Table 3.4. In most of these products,
the API is presolubilized either in an oral solution or as solution in soft capsules, due to
the low effectiveness of the incorporation of drugs into micelles is not effective by a sim-
ple equilibration inwater [44]. The step of solubilizing and incorporation of non-dissolved
drug by a potent solubilizermight also be too slow to be realized throughout the intestinal
passage. Therefore, drug loading in liquid dosage forms can be facilitated by techniques
such as dialysis against water or evaporation from an organic solvent [44]. The novel solu-
bilizing agent Soluplus R offers the possibility of a good solubility enhancement in combi-
nation with a fast dissolution to drug loaded micelles if applied in form of a solid solution
[45].
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glassy
solid
solution
solid
solution
glass suspension eutectic amorphous
precipita-
tion
phases 1 1 2 2 2 2
drug molecularly
dispersed
molecularly
dispersed
amorphous crystalline crystalline amorphous
carrier amorphous crystalline amorphous amorphous crystalline crystalline
Table 3.5.: Classiϐication for solid dispersions upon amorphous or crystalline state of drug
and carrier, according to [47]
3.3. Solid dispersions and hot melt extrusion
3.3.1. Solid dispersions for pharmaceutical applications
Solid dispersions offer a novelway for the formulation of poorly aqueous soluble drugs. By
deϐinition a solid dispersion is the dispersion of an API in a solid matrix [46]. Based upon
the amorphous or crystalline state of the used drug and the carrier, solid dispersions may
be classiϐied as described in Table 3.5. A solid solution is therefore present if the drug is
molecularly dispersed in the solid matrix. As for a usual liquid solution, those systems
consist of a single phase. Contrarily, a glass suspension is a biphasic system whereas the
crystalline or amorphous API is dispersed in an amorphous matrix. Since pharmaceutical
polymers are usually of amorphous nature, only three of the solid dispersions described
in Table 3.5 may occur: glassy solid solutions and both glass suspension types.
These types show differences in their stability: While a dispersion of a crystalline drug in
the polymer is almost stable, a dispersion of an amorphous API in the polymermatrixmay
be affected by crystallization during storage and processing (e.g. milling, tableting). The
most desired form for the formulation of poorly soluble drugs is the glassy solid solution,
whereas the drug is molecularly dissolved in the polymer. In this case, the concentration
of the drug in the solid solution must be below its saturation solubility in the respective
polymer. Therefore, this type of solid solution is thermodynamically stable, just as a com-
mon liquid solution. As the drug is molecularly dissolved, the absolute minimum of its
particle size is reached (= the molecular diameter) [48]. Thereby, the dissolution rate is
determined by the dissolution of the polymeric carrier [48]. Such a rapid dissolution of
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the solid solution leads to a supersaturation of the drug in the dissolutionmedia. If no sta-
bilizing agents are present, a supersaturation is very unstable. A supersaturated solution
of an API may be stabilized by solubilizing agents as described above (see Chapter 3.2).
Also the carrier itself may act as stabilizer for the so formed supersaturated solution [48].
The novel excipient Soluplus R provides both: The capability to form solid solutions and
the formation of micelles in aqueous solution as result of its amphiphilic structure.
Thepreparationof solid dispersionsmaybe realized either by the solventmethodorby the
hot melt method. The solvent method was introduced by Tachibani and Nakamura [49].
In this method, the solid solution is produced by cosolvation of both drug and carrier in
a liquid solvent, followed by an evaporation of the solvent under vacuum. The evapora-
tion of the solvent may also be realized by other common methods, such as freeze-drying
or spray-drying [50, 51]. As organic solvents are often used for this method, the solvent
must be evaporated completely due to toxicity reasons. Another problem of this method
may be that by evaporating a solvent, small variations in the setup lead to high variations
in the product [48]. The main advantage of this method compared to hot melt methods is
its applicability on heat-sensitive drugs, especially in combination with carriers providing
a high melting point.
3.3.2. Hot melt extrusion
The hot melt method was introduced by Sekiguchi and Obi in 1961 for an eutectic mix-
ture of sulfathiazole and urea [52]. In this simple approach both substances were molten
together and cooled in an ice bath. The cooling step establishes a supersaturation of the
drug which is then stabilized by the solid matrix. It depends on the miscibility of drug
and matrix in the molten form if the product appears as a molecularly dispersed system
[48]. The stability of the thereby reached supersaturation during the cooling process is
also dependent on the process itself. This led to improvements in the cooling rate, such as
snap-cooling on stainless steel [53, 54] or by spraying the melt on a cool plate [55]. The
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Figure 3.7.: The number of patents for hot melt extrusion for pharmaceutical applications
strongly increased from 1982–2006. Adopted from [58]
main limitation of the melting process is the application to thermolabile drugs. However,
the introduction of hot melt extrusion to pharmaceutical applications led to fast process-
ing times, reducing the stress the APIs to a minimum. Also the addition of plasticizers
improved the applicability ofmelt processes to thermosensitive drugs, as the process tem-
peratures could be reduced [56, 57].
Hot-melt extrusion is deϐined as the process of pumping rawmaterialswith a rotating screw
under elevated temperature through a die into a product of uniform shape [58]. This process
is origined in plastics industry and was ϐirst used for the production of plastic insulations
for wires in the mid-19th century [58]. Nowadays, hot melt extrusion is still an important
process for plastics industry, but also gains more and more interest for pharmaceutical
applications (Figure 3.7). After the ϐirst use of this technique for delayed release dosage
forms in the 1970s [59], hot melt extrusion is today an attractive process for the produc-
tion of diverse drug delivery systems [58, 60, 61]. The advantages of hot melt extrusion
compared to other production techniques for solid dispersions are numerous: it’s a fast
and continuous process, which is also easy to scale-up. Furthermore, the product of the
extrusion is ready for further steps as milling or pelletizing without any preceding drying
step.
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Figure 3.8.: General setup of an extruder, adopted from [62]
Extruders for pharmaceutical applications are similar to those for other industries, but
with adaption to regulatory requirements. Hence, these extruders are generally made of
an inertmaterial such as stainless steel and constructed tomeet the cleaning standards for
drug manufacturing [62]. Generally, an extruder consists of one or two transport screws
which rotate enclosed in a cylinder (Figure 3.8). During the extrusion process the product
is molten, mixed and ϐinally shaped by the passage through a die. Mixing and kneading of
the material is usually established by the application of conveying and mixing elements,
applied on the extruder screw [61, 62].
Polymers used for hot melt extrusion have to meet several requirements for a success-
ful formation of a solid dispersion. It has to be thermoplastic, has to provide an appro-
priate glass transition temperature (Tg) and has to be stable at the applied temperatures
(50–180 C). Furthermore, it has to be non-toxic for pharmaceutical applications. The sol-
ubilization capacity of the used polymer is most important for the production of a molec-
ularly disperse extrudate. The solubility parameters for a polymer are similar to those
of a liquid solvent, including H-bond donors & acceptors, amide groups and a sufϐicient
lipophilicity for poorly soluble drugs [63, 64]. The alchemist rule similia similibus sulvun-
tur (lat.: like dissolves like) is valid for solid solvents as well as for liquid solvents.
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Figure 3.9.: Chemical structure of Soluplus R. PEG 6000/vinylcaprolactam/vinyl acetate
are polymerized in a ratio of 13/57/30, according to [62]
Molecular weight  118000 g/mol
Glass transition temperature (Tg)  70 C
CMC 7.6 mg/l = 7.6 ppm
K-value (1% ethanol) 31–41
Lower crystalline solution temperature (LCST)  40 C
Solubility
water soluble
acetone up to 50%
methanol up to 45%
ethanol up to 25%
DMF up to 50%
Table 3.6.: Physico-chemical properties of Soluplus R
3.4. The novel solubility enhancer Soluplus R
Soluplus R is an amphiphilic polymer with the chemical formula: polyvinyl caprolactam-
polyvinyl acetate-polyethyleneglycol graft copolymer (Figure 3.9). This graft copolymer
provides a polyethylene glycol backbone as hydrophilic part and vinylcaprolactam/vinyl
acetate sidechains as lipophilic structure. Therefore, it formsmicelles in aqueous solution
above the CMC of 7.6 mg/l. This polymeric excipient was designed for (micellar) solubi-
lization of poorly aqueous soluble compounds and for the feasibility of forming solid solu-
tion through hot melt extrusion. The main physico-chemical parameters of Soluplus R are
summarized in Table 3.6. Especially the comparably low Tg qualiϐies Soluplus R as well
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Figure 3.10.: Solubility of several drugswith andwithout Soluplus R (10%w/w), adopted
from [45]
suitable for hot melt extrusion, since the process temperatures can be reduced. Further-
more, Soluplus R can easily be used in tablets as it is a solid powder, that also can act as
binder [45].
Due to its amphiphilic structure Soluplus R forms micelles in aqueous solution which can
solubilize poorly soluble APIs. It was shown that Soluplus R enables a many fold super-
saturation for several drugs (Figure 3.10). In form of a solid solution, manufactured by
hot melt extrusion the dissolution rate of poorly soluble APIs was strongly increased [84].
Furthermore, the oral bioavailability of themodel drugs danazol, fenoϐibrate and itracona-
zole (Figure 3.12) was strongly increased if applied as solid solution [84, 45]. This result
stands in strong agreement with Amidon’s biopharmaceutics classiϐication system (BCS)
which predicts a high oral bioavailability for BCS class II substance if their characteristic
solubility problems are circumvented.
3.5. The Caco-2 cell culture model
Caco-2 cells were isolated from a human colon adenocarcinoma of a 77 year-oldmale cau-
casian. Caco-2 monolayers are a well established and characterized model for the small
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Figure 3.11.: Left: Cross section of Caco-2 monolayer. Right: Cross section of porcine in-
testinal mucosa
intestine [65, 66]. Permeability assays using Caco-2 cells are routinely used in pharma-
ceutical research and development [67, 68]. Additionally Caco-2 cells are used for investi-
gations in drug-transporter interactions as well as in intestinal drug metabolism [69, 70].
The usability of this cell line as model for the intestinal barrier can be explained by its
behavior under cell culture conditions. Caco-2 cells differentiate to cells, phenotypically
similar to human small intestine enterocytes (Figure 3.11). Accordingly, Caco-2 cells pro-
vide microvilli, tight junctions, transporter proteins (e.g. P-glycoprotein) and also a wide
range of metabolic enzymes [71, 72]. Furthermore, Caco-2 cells differentiate to polarized
monolayers, forming an apical and a basolateral side [73]. Growing Caco-2 cells on perme-
able ϐilters establishes the possibility to investigate drug transport across cell monolayers
[66, 65]. Good in-vitro-in-vivo correlations (IVIVC) were found between drug permeabil-
ity across Caco-2 monolayers and the intestinal absorption [11, 72, 74]. The expression
of active transporters (inϐlux & efϐlux) such as MCT1, OATP-B, MDR1, MRP2 and BCRP in
Caco-2 cells underlines the potential of this cell line as an excellent predictive tool for in-
testinal drug absorption [75]. Although expression of these proteins can be observed in
Caco-2 cells, their expression levels differ from those in the human body [76]. Especially
the metabolic active enzyme CYP3A4 is only poorly expressed in Caco-2 cells. However,
there are approaches to avoid these limitations for example by the use of CYP3A4 induced
[77] or transfected [78] cell lines.
General differences between Caco-2 cells and the intestinal membrane lead to further lim-
itations of this model. The human intestinal membrane not only consists of enterocytes
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but also of goblet cells. Goblet cells produce mucus, forming a thin layer on the luminal
side of the intestinal barrier. This mucus layer might inϐluence the intestinal drug absorp-
tion: Firstly, it is gel-like and may hinder drug diffusion by its high viscosity. Secondly, the
mucus layer provides a pH gradient which may inϐluence the solubility of basic or acidic
drugs [79]. Furthermore, this mucus layer might be the aim of gastroretentive dosage
forms, using mucoadhesive excipients [80]. To reduce this gap between Caco-2 monolay-
ers and the intestinal membrane co-cultures of Caco-2 cells and goblet like cell lines (e.g.
HT29 cells) were developed [81, 82, 83]. Although these co-cultures provide an in-vivo-
likemucus layer, they couldn’t replace Caco-2 monocultures as they didn’t showmuch su-
perior in-vitro-in-vivo correlations, justifying higher costs and efforts. Another difference
betweenCaco-2 cultures and the real intestine is the speciϐically higher tightness of the cell
culture model [66]. This is also expressed in a higher transepithelial electrical resistance
(TEER value) of Caco-2 monolayers compared to the original membranes [11]. The TEER
value is an acceptedmeasure for the tightness of cell monolayers, grown on permeable ϐil-
ters. Therefore, the electrical resistance between the apical and basolateral compartment
of such a system (e.g. Transwell) is measured by an electrical Volt-Ohm meter (EVOM).
As result of their higher tightness, the paracellular transport route (Figure 3.2 B) is hin-
dered. Accordingly the transport of hydrophilic drugs, which are mainly transported via
this route, is often underestimated in the Caco-2 model [72]. Therefore, Caco-2 mono-
layers show better predictions of intestinal absorption for highly permeable substances
(BCS class I,II), which are generally more lipophilic and transported via the transcellular
pathway (Figure 3.2).
3.6. Aims of this thesis
In this work Soluplus R, a novel solubilizing agent was characterized for its interaction
with poorly soluble drugs and the intestinal mucosa. Caco-2 cell monolayers were used as
in vitromodel for the intestine. Formulations of Soluplus Rwith poorly soluble drugswere
investigated for their transport behavior and their potential to increase the oral bioavail-
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Figure 3.12.: Chemical structure of the used model drugs danazol, fenoϐibrate and
itraconazole
ability of these drugs. Additionally, this work furthered the understanding of the interplay
between a solubilizing excipient, the drug and the mucosa. These interactions play an im-
portant role for the liberation and absorption part of the LADME scheme. Additionally,
the interaction between Soluplus R and bioactive proteins (P-glycoprotein, trypsin) was
investigated which might also interact with the absorption of poorly soluble drugs.
The aims of this thesis may be summarized as:
1. Evaluation of the Caco-2 model as surrogate for in vivo behavior of Soluplus R for-
mulations
2. Testing Soluplus R for a possible inhibition of human P-glycoprotein
3. Optimization of Soluplus R formulations, using the Caco-2 model
3.6.1. The Caco-2 model as predictive tool for Soluplus R formulations
In this work the Caco-2 monolayer model was evaluated for its predictive value for for-
mulations with Soluplus R. While the Caco-2 monolayer model is widely accepted as sur-
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rogate for pure drugs, the application of more complex excipient/drug is not well estab-
lished. Therefore, this workmight help to fulϐil the aim of reducing, reϐining and replacing
(3R-rule) animal experiments.
The starting point of this thesis were in vivo pharmacokinetic studies of Soluplus R for-
mulations with danazol, fenoϐibrate and itraconazole. This data was collected in animal
experiments in beagle dogs. According to this animal experiments, the solid solution of
Soluplus R and the respective drugs showed a many fold increase in AUC and Cmax values
compared to the pure drug. Furthermore, a physical mixture of Soluplus R and the respec-
tiveAPIwas administered to the animalswhichwasonly effective in the case of fenoϐibrate.
As ϐirst aim of this thesis, the possibility of predicting in vivo data of Soluplus R formula-
tions by the Caco-2 model should be proven.
3.6.2. Potential inhibition of P-glycoprotein and/or trypsin by Soluplus R
As many non-ionic surfactants were shown to inhibit P-glycoprotein or other active pro-
teins, Soluplus R was tested for its inhibitory potential on a) P-glycoprotein as transmem-
braneous active transporter and b) trypsin as soluble enzyme, present in the GI.
3.6.3. Optimization of Soluplus R formulations
After establishment of the methods to use Caco-2 cells as a surrogate for in vivo data of
Soluplus R formulations, the Caco-2 tool was used for optimization of such formulations.
Especially the effect of the ratio between excipient and drug in hot melt extrudates was
investigated. The aim of this part was to discover an optimal Soluplus R/drug ratio, as
result of the interactions in binding, solubilization and crystallinity of drug and excipient.
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4. Soluplus R as an effective absorption
enhancer of poorly soluble drugs in vitro
and in vivo
Parts of this chapter have been published as journal article:
Soluplus R as aneffective absorptionenhancerof poorly solubledrugs in vitroand in
vivoMichael Linn, Eva-Maria Collnot, Dejan Djuric, Katja Hempel, Eric Fabian, Karl Kolter,
Claus-Michael Lehr
European Journal of Pharmaceutical Sciences Article in press
Abstract
As many new active pharmaceutical ingredients are poorly water soluble, solubility en-
hancers are one possibility to overcome the hurdles of drug dissolution and absorption in
oral drug delivery. In the present work a novel solubility enhancing excipient (Soluplus R)
was tested for its capability to improve intestinal drug absorption. BCS class II compounds
danazol, fenoϐibrate and itraconazole were tested both in vivo in beagle dogs and in vitro
in transport experiments across Caco-2 cell monolayers. Each drug was applied as pure
crystalline substance, in a physical mixture with Soluplus R, and as solid solution of the
drug in the excipient. In the animal studies a many fold increase in plasma AUC was ob-
served for the solid solutions of drug in Soluplus R compared to the respective pure drug.
An effect of Soluplus R in a physical mixture with the drug could be detected for fenoϐi-
brate. In vitro transport studies conϐirm the strong effect of Soluplus R on the absorption
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behavior of the three tested drugs. Furthermore, the increase of drug ϐlux across Caco-2
monolayer is correlating to the increase in plasma AUC and Cmax in vivo. For these poorly
soluble substances Soluplus R has a strong potential to improve oral bioavailability. The
applicability of Caco-2 monolayers as tool for predicting the in vivo transport behavior of
the model drugs in combination with a solubility enhancing excipient was shown. More-
over, the improvement of a solid dispersion compared to physical mixtures of the drugs
and the excipient was correctly reϐlected by Caco-2 experiments. In the case of fenoϐi-
brate the possible improvement by a physical mixture was demonstrated, underscoring
the value of the used tool as alternative to animal studies.
4.1. Introduction
According to the biopharmaceutical classiϐication system (BCS), the dissolution of poorly
water-soluble drugs in gastrointestinal media is the limiting step for its permeation and
absorption through the intestinal system [7, 9]. Thus, the aim of many formulation at-
tempts is to increase drug solubility in physiological ϐluids by means of surface-active ex-
cipients which can act as wetting agents and solubilizers. Other methods for improving
oral drug solubility include nanosizing or the use of cyclodextrin complexes [85, 48, 86]. In
recent years, the emergence of the hot melt extrusion technique has enabled the formula-
tion of solid solutions of poorly soluble drugs in polymer matrixes such as polyethyleneg-
lycol, polyvinylpyrrolidone or cellulose derivatives (e.g. hydroxypropylmethylcellulose).
In a solid solution the drug is molecularly dispersed in the solid matrix. After fast dissolu-
tion, a supersaturated solution is formed, allowing high drug ϐluxes. [48].
In the present study, polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft co-
polymer (Soluplus R), a new polymer with amphiphilic properties was used. Soluplus R
shows excellent solubilizing properties for BCS class II substances and offers the possi-
bility of producing solid solutions by hot-melt extrusion. The dissolution of poorly sol-
uble drugs in aqueous media can be highly improved by the use of solid solutions with
Soluplus R [84]. The ability of Soluplus R to improve oral bioavailability of poorly soluble
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Molecular
weight [g/mol]
Melting point
[C]
logP pKa Solubility
(water)
[µg/ml]
Solubility
(10%
Soluplus R ;
phosphate
buffer) [µg/ml]
Solubility in
used physical
mixture
formulation
[µg/ml]
Danazol 337.46 224.4–226.8 4.5[9] -  1[9] 730[45] 4.8
Fenoϐibrate 360.831 80.5 5.2[87] - 0.1[88] 170[45] 5.2
Fenoϐibric acid 318.76 179–183 3.99 3.09 70 n.d. n.d.
Itraconazole 705.64 166.2 5.7[89] 3.7[89]  0.001[90] 130[45] 2.7
Table 4.1.: Physico-chemical parameters of model drugs
drugs was investigated using three different BCS class II drugs, danazol, fenoϐibrate and
itraconazole, their physico-chemical parameters are shown in Table 4.1.
Danazol, a testosterone derivative suppressing luteinizing and follicle stimulating hor-
mone used for the treatment of endometriosis [91], shows a low relative bioavailability
of 5.1 ± 1.9% as determined in beagle dogs, due to its poor aqueous solubility (10 µg/ml)
[92]. Its oral bioavailability could be raised by different formulation techniques using
nanoparticles or cyclodextrin complexes up to 82.3 ± 10.1% and 106.7 ± 12.3%, respec-
tively [92]. Furthermore, danazol formulations with polyvinylpyrrolidone obtained by ul-
tra-rapid freezing or spray freezing processes showed enhanced dissolution rates in vitro
[93, 94].
The lipid modifying drug fenoϐibrate with an aqueous solubility of 0.1 µg/ml is less solu-
ble than danazol. Sant et al. discovered polymeric micelles of poly(ethylene glycol)-block-
poly(alkyl acrylate-co-methacrylic acid) as an efϐicient solubility enhancer [95]. Fenoϐi-
brate dissolution can also be improved by nanosizing, spray-drying or cogrinding of the
drug [96]. Buch et al. showed the effectiveness of a melt-extruded solid solution, lipid mi-
croparticles, micronized and nanosized fenoϐibrate on intestinal drug absorption versus
fenoϐibrate bulk ware in vivo as well as in a combined dissolution/permeation system in
vitro [97].
The antifungal drug itraconazole is practically insoluble in water and has the highest logP
of the drugs used in this study. It is a weak base with a pKa of 3.7 and appears ion-
ized in gastric ϐluids with a pH lower than 3 resulting in pH dependent intestinal absorp-
tion [98]. Itraconazole is commercialized as Sporanox R capsules, where it is applied as a
drug/polymer layer with HPMC on neutral pellets. Six et al. developed a fast dissolving,
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but not homogenous solid solution of itraconazole and HPMC [99]. Other solid solutions
of itraconazolewere introduced byMiller et al. who generated a ternary solid solution, ob-
tained by hot-melt extrusion of itraconazole in a matrix formed by Carbopol R 974P and
Eudragit R L100-55 [100]. Buchanan et al. showed an increased oral bioavailability apply-
ing itraconazole as a formulation with hydroxypropyl-β-cyclodextrin (HPβCD) HPβCD is
as well used as solubilizer for itraconazole in the commercialized Sporanox R for injection
[101].
Solid solutions are usually characterized by their crystallinity and their dissolution be-
havior. However, as permeation across the intestinal epithelium is missing, merely per-
forming in vitro solubility will not always afford an in vivo prediction. In particular, the
interplay between drug, excipient and epithelial cells cannot be investigated in a cell free
setup.
Caco-2monolayers are a widely used in vitro tool to predict permeation behavior of drugs
over the intestine [66, 74, 102]. In general, drugs are applied as solutions to the apical
side of the in vitro model and drug permeation rate to the basolateral side is correlated
to the in vivo absorbed fraction of the drug or directly to the AUC. The Caco-2 model has
also been successfully applied to study the inϐluence of pharmaceutical excipients on drug
permeation not only via solubility enhancement but also via modulation of tight junction
functionality and active transport systems [103, 30, 104]. Hence, the Caco-2monolayer as-
say has been successfully used to evaluate complex formulations such as nanoparticulate
formulations and self-emulsifying systems. Nevertheless, there is still need for further
evaluation in particular with regards to experimental design and to acceptor and donor
media chosen [105].
In the present study, weused the Caco-2 in vitromodel to predict the effect of Soluplus R on
oral bioavailability of three BCS class II compounds. Drug permeation from the pure crys-
talline substance and from the physical mixtures of drug and excipient were compared to
the respective aqueous dispersed solid solutions. Drug afϐinity to Soluplus R was studied
by equilibrium dialysis to allow interpretation of possible differences in Soluplus R efϐi-
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%API [w/w] Temperature [C] Powder feed rate [kg/h] rpm
Danazol 15 140 0.9 200
Fenoϐibrate 20 95 0.7 200
Itraconazole 15 150 1 200
Table 4.2.: Melt extrusion parameters for production of the used solid solutions
cacy. Data obtained in the transport experiments was compared to data from in vivo stud-
ies in beagle dogs, validating the ϐindings from the cell culture setup and demonstrating
its strengths and weaknesses for the testing of complex formulations.
4.2. Materials and Methods
4.2.1. Chemicals
The solubility enhancer Soluplus R was provided by BASF SE (Ludwigshafen, Germany).
Danazol and itraconazole were donated by Selectchemie AG (Zurich, Switzerland). Dul-
becco’s modiϐied Eagle’s medium (DMEM) and non-essential amino acids were obtained
from PAA Laboratories GmbH (Pasching, Austria). Fetal bovine serum (FBS) was pur-
chased from PAN-Biotech GmbH (Aidenbach, Germany). Vitamin E TPGS 1000 was sup-
plied by Eastman Chemical Company (Kingsport, TN, USA). Transwell permeable mem-
brane inserts (type 3460, 0.4 µm pore size, polycarbonate) were from Corning Incorpo-
rated Life Science (Lowell, MA, USA). Fenoϐibrate and all other chemicalswere fromSigma-
Aldrich (St. Louis, MO, USA).
4.2.2. Solid Solutions
Solid solutionswerepreparedbyhotmelt extrusion in aThermoFisher Polylab twin-screw
extruder (ThermoFisher Scientiϐic Inc., Watham, MA, USA). Extrusion parameters were
adjusted for each drug and are summarized in Table 4.2. The solid solutions employed
in this study contained 15% API for danazol and itraconazole and 20% for fenoϐibrate,
respectively.
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4.2.3. Caco-2 cell culture
Caco-2 cells of clone C2BBe1were obtained fromAmerican Type Culture Collection (Man-
assas, CA, USA). Cells were grown in an incubator at 37 C with an atmosphere of 5% CO2
and 80% relative humidity. Cell culturemediumwas DMEM, containing 10%FBS and 1%
NEAA and was changed every 2-3 days. Every 7 days cells were passaged at a conϐluence
of about 90%. Cell passages 65–75 were used for transport experiments. For transport
experiments cells were seeded on Transwell permeable membrane inserts (0.4 µm pore
size, 1.12 cm2 membrane area) at a density of 60000 cells per well. Fully differentiated
cells were used for transport experiments after 21–23 days in culture. Only monolayers
with a transepithelial electrical resistance (TEER) higher than 500 Ohm x cm2 were qual-
iϐied for transport assay.
4.2.4. Caco-2 transport experiments
Transportmediumwas Krebs Ringer buffer (KRB) containing 114.2mMNaCl, 3.0mMKCl,
4.0mM d-glucose, 1.4mM CaCl2, 2.6mM MgCl2, and 10.0mM HEPES. pH was adjusted by
NaOH to a ϐinal value of 7.4. 0.2% Vitamin E TPGS 1000 was added to the buffer to main-
tain sufϐicient drug solubility in the receiver compartment, as described by Mellaerts et
al [106]. For itraconazole, a known substrate of the P-gp efϐlux system, transport studies
were conducted using KRB + 1% HPβCD as acceptor medium, since Vitamin E TPGS is
known to inhibit P-gp and thus might interfere with the transport experiment.
The following formulations of each drug were used for transport experiments: I) the pure
crystalline drug, II) a physical mixture of the drug and Soluplus R in the same ratio as in
the respective solid solution and III) the solid solution of the drug in Soluplus R. All formu-
lations were suspended in KRB and diluted to a ϐinal drug concentration of 0.5 mg/ml for
danazol and itraconazole and of 1.0mg/ml for fenoϐibrate. The suspensions were stirred
for 1.0 h on a magnetic stirrer to simulate gastrointestinal dissolution. Throughout this
timescale the solid solutions dissolve and enable a micellar-stabilized supersaturation of
the respective drug. Cells werewashed twice and pre-incubatedwith KRB for 1.0 h. 500 µl
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of each drug suspension was applied on the apical side, while 1500 µl of the respective
acceptor medium was placed on the basolateral side. Transport experiments were con-
ducted in a cell culture incubator at 37 C, 80% rH, 5% CO2 and the system was agitated
on an orbital shaker at 100 ± 20 rpm. Samples of 200 µl volume were taken at 30, 60, 90,
120 and 180minutes from the basolateral side. The lost volume was replaced by fresh
tempered buffer. TEER measurements as control for membrane integrity took place at
the beginning and after the experiment.
Drug ϐluxwas calculated over the linear range of the permeation curve for eachwell, using
the formula:
Flux =
dc
dt
 1
A
(4.1)
whereas dc/dt indicates the slope of the permeation curve and A the surface of the mono-
layer.
4.2.5. Sample preparation & HPLC analysis
Samples, as drawn from the basolateral compartment, were diluted in a 1:1 ratio either
with acetonitrile (fenoϐibrate, itraconazole) or with methanol (danazol). For danazol a
methanol:water:phosphate buffer pH 6.8 [80:17:3 (v/v/v)] mixture was used as mobile
phase. 50 µl of the sampleswere injected on a reversed phase column [LiChroCART R 125-
4 LiChrospher R 100 RP18 (5 µm) byMerck KGaA (Darmstadt, Germany)] and detected by
UV-VIS absorption at 288 nm.
Fenoϐibrate samples were injected at a volume of 50 µl on a reversed phase column [RP 18
(5 µm) as above] using a mixture of 30 volumes water acidiϐied to pH 2.5 by phosphoric
acid and 70 volumes acetonitrile. Due to enzymatic hydrolysis, fenoϐibrate was detected
as the mother compound and as its metabolite fenoϐibric acid by UV-Vis absorption at 286
nmwith retention times of 6.4 and 2.3minutes respectively.
The mobile phase for itraconazole consisted of a mixture of acetonitrile, water and pH 6.8
phosphate buffer (70:27:3 [v/v/v]). A volume of 80 µl was injected on a reversed phase
column (RP 18 (5 µm) as above) and detected at a wavelength of 263 nm (see Appendix C
for further details).
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4.2.6. Animal studies
The investigated formulationswere administered as oral application via capsule to female
fastedbeagle stockdogs (n=5/per test substance preparation). PurebredBeagle dogs (7–8
months; danazol; 20–22 months for itraconazole and fenoϐibrate) were selected, as this
non-rodent species is recommended by the guidelines and there is extensive laboratory
experience with this strain of dogs. Dogs were housed in animal rooms with forced venti-
lation system and additional heating in winter. The animals had free access to inner and
outer kennels of at least 6m2. Dog diet was offered in the mornings for a period of two
hours. The animals had free access to water by and automatic watering device.
Before drug administration, food was withdrawn for at least 22 hours, but access to water
wasmaintained. Onexperimentdays, thedogswere fedabout2 hours after administration
of the test substances (following the blood sampling after 2 h). Appropriate amounts of
drug preparations, adjusted on the basis of each individual animals weight, were weighed
and placed in gelatin capsules, size 11 (Torpac Inc., Fairϐield, NJ 07004, USA) and ad-
ministered to the dogs in the morning: I) Crystalline API, II) a physical mixture of API
and Soluplus R and, III) a solid solution of API and excipient (as described in 4.2.2). The
administered doses were 10mg/kg bodyweight for itraconazole and fenoϐibrate and 30
mg/kg bodyweight for danazol, respectively. Dose levels were selected based on liter-
ature data: [107, 108] (fenoϐibrate), [101] (itraconazole), [92] (danazol). Experiments
were performed according to German Animal Welfare legislation under the license num-
ber 1.577-07/873-50. The laboratory is AAALAC (Association for Assessment andAccred-
itation of Laboratory Animal Care) certiϐied.
Blood samples for kinetic investigations (approx. 3ml each) were taken prior to adminis-
tration and after 0.5, 1, 2, 4, 6, 8 and 24 h from the Vena cephalica antebrachii and collected
into lithium heparin blood collection tubes. After centrifugation, plasma was divided into
two equal parts and transferred into plastic tubes and placed on dry ice until storage at -20
± 5 C. One aliquot of each sample was subsequently transferred frozen to the analytical
laboratory of BASF for analysis. The remaining aliquot was stored as contingency sample.
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Plasma samples were diluted by addition of acetonitrile [1:9 (v/v)]. After centrifugation
at 5,000 rpm, the received supernatant was analyzed by appropriate LC-MS-, LC-MS/MS-
analyses in the linear range of the quantiϐication method. The linear range was assessed
by standard solutions of the test compounds in the same matrix. See Appendix C for fur-
ther details on the used LC-MS methods.
AUC levels were determined based on analyzed plasma concentrations by application of
the linear trapezoid calculation method using a BASF internal Microsoft Excel based ki-
netic assessment tool. For the performed experiments single animal plasma values at the
different timepointswere transferred into the programand single animal AUCvalueswere
calculated. Mean AUC values and standard deviations were used in the results section.
4.2.7. Equilibrium dialysis
Dialysis experiments were performed to investigate binding behavior of the investigated
drugs to Soluplus R. Studies were performed in a DIANORM apparatus (identical to DI-
ALYZER by Harvard Apparatus, Holliston, MA, USA) with a working volume of 2 ml per
dialysis chamber. For our experiments, suspensions of a physical mixture of 0.5% Solu-
plus R and 0.5mg/ml (danazol and itraconazole) or 1.0mg/ml (fenoϐibrate and fenoϐib-
ric acid) respectively were prepared in KRB by stirring on a magnetic stirrer for 24 h.
The dispersions were centrifuged to eliminate non-dissolved drug, resulting in saturated
drug-excipient solutions. The donor chambers of the dialysis cell were ϐilled with 2ml of
these suspensions. The acceptor sides, separated by a cellulose membrane with a cutoff
of 10 kDa (Harvard Apparatus, Holliston, MA, USA), were ϐilled either with KRB + 1% BSA
or KRB + 0.2% Vitamin E TPGS 1000 at the same volume. Dialysis was performed over
four hours at a rotation speed of 20 rpm at 37 C. A control experiment using ϐluorescein
sodium as model substance showed that equilibrium was reached throughout this time
scale (data not shown). Samples from donor and acceptor were analyzed by HPLC as de-
scribed above. Results are expressed as donor/acceptor ratio (D/A ratio) serving as an
indicator for drug binding to Soluplus R.
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Figure 4.1.: a) Danazol transport across Caco-2 monolayers (n=3–6; mean ± SD) b) In vivo
blood levels of danazol applied to beagle dogs (n=5; mean values)
4.3. Results
4.3.1. Danazol
Danazol transport across Caco-2monolayerswas demonstrated for all three formulations.
As shown in Figure 4.1a, the highest transport rate in vitrowas reached from the solid so-
lution of Soluplus R and the danazol. The pure crystalline substance and the physical mix-
ture showed no signiϐicant difference in transport rate. The solid solution enabled a drug
ϐlux of 20.61 ngmin-1  cm-2 ,a 8-fold increase (Figure 4.2) compared to the pure drug
which afforded a ϐlux of 2.67 ngmin-1 cm-2. In vivo experiments in beagle dogs showed
a 15-fold increase in plasma AUC from 329ng hml-1 for the pure drug up to 5081 ng
 h  ml-1 for the solid solution after oral administration. For the physical mixture no
signiϐicant effect of Soluplus R was determined compared to the pure drug (Figure 4.1b).
Besides increased AUC, an increased Cmax was shown for the solid solution compared to
the pure drug. Cmax and Tmax values are summarized in Table 4.3.
4.3.2. Fenoϐibrate
Since fenoϐibrate is mostly hydrolyzed to fenoϐibric acid either by a ϐirst pass effect in the
animal or by hydrolytic enzymes present in Caco-2 cells, all results refer to fenoϐibric acid.
34
CHAPTER 4. SOLUPLUS R AS AN EFFECTIVE ABSORPTION ENHANCER OF POORLY
SOLUBLE DRUGS IN VITRO AND IN VIVO
Figure 4.2.: Effect of Soluplus R on danazol ϐlux across Caco-2 monolayers and on AUC in
beagle dog animal study (n=3–6 for in vitro data, n=5 for in vivo data. Mean ±
SD)
With a drug ϐlux of 99.33 ng  min-1  cm-2 the solid solution of fenoϐibrate showed the
highest transport rate, followed by the physical mixture at 53.91 ng  min-1  cm-2 and
the pure drug at 34.46 ngmin-1  cm-2 (Figure 4.3a).
In animal experiments increased absorption of the drug was detected when fenoϐibrate
was formulated with Soluplus R (Figure 4.3b). Both formulations containing Soluplus R
showed a strong increase in plasma AUC as well as in Cmax values (Table 4.3). No signiϐi-
cant difference was detected between the solid solution and the physical mixture of drug
and excipient, both showing an AUC of about 60,000 ng  h  ml-1 , an almost 5-fold in-
crease compared to the unformulated crystalline drug.
Comparing in vitro and in vivo results (Figure 4.4), drug ϐlux was highest for the solid so-
lution and the AUC of solid solution and physical mixture were on the same high level.
The physical mixture therefore showed a stronger effect on drug absorption in vivo than
in vitro.
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Figure 4.3.: a) Fenoϐibrate transport across Caco-2 monolayers. Transported amount ex-
pressed as fenoϐibric acid (n=3-6; mean ± SD) b) Fenoϐibric acid in blood sam-
ples of in vivo study in beagle dogs (n=5; mean values)
Figure 4.4.: Effect of Soluplus R on fenoϐibrate ϐlux across Caco-2 monolayer and on AUC
in animal study (n=3-6 for in vitro data, n=5 for in vivo data. Mean ± SD)
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Figure 4.5.: a) Itraconazole transport across Caco-2 monolayers (n=3; mean ± SD) b) Itra-
conazole bioavailability study in beagle dogs (n=5; mean values)
4.3.3. Itraconazole
Itraconazole is characterized by a very poor aqueous solubility below 0.1 µg/ml, result-
ing in a low donor concentration. Thus, from the pure crystalline substance and from the
physical mixture only very low transport rates just at the analytic limits were detected
(Figure 4.5a). For the pure drug the transported amount of itraconazole was below the
limit of quantiϐication, therefore no calculation of a ϐlux value was possible. The physi-
cal mixture showed a ϐlux of 0.458 ng  min-1  cm-2. In contrast, the solid solution of
itraconazole in Soluplus R showed a high transport rate across Caco-2 cells, resulting in a
drug ϐlux of 14.51 ngmin-1  cm-2 an about 30 times increase compared to the physical
mixture.
In vivo, the solid solution showed a plasma AUC of 2212 ng  h  ml-1. For the physical
mixture the AUC was 77 ng  h  ml-1, while no AUC could be determined for the crys-
talline substance, since no or only low drug amounts reached the blood (Figure 4.5b &
Figure 4.6). The more than 30-fold increase in AUC is in line with strong in vitro effect of
the solid solution of itraconazole in Soluplus R.
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Drug
Form
ulation
AUC
(in
vivo)[ng
h

m
l -1]
Cm
ax (invivo)
[ng/m
l]
T
m
ax (invivo)
[h]
Rel.AUC
Flux(invitro)
[ng
m
in -1

cm
-2]
Rel.Flux(in
vitro)
Crystalline
329±58
37.6
2
1
2.67±0.23
1
Danazol
Physical
m
ixture
261±143
20.6
4
0.8
2.63±0.25
0.98
Solidsolution
5081±2174
1238.6
2
15.4
20.61±1.37
7.7
Crystalline
12201±8080
1492.2
4
1
34.46±2.76
1
Fenoϐibrate
Physical
m
ixture
64830±9299
5509.0
4
5.3
53.91±1.33
1.56
Solidsolution
54167±
14775
5262.0
4
4.4
99.33±4.48
2.88
Crystalline
-
-
-
-
-
-
Itraconazole
Physical
m
ixture
77±52
19
4
-
0.46±0.01
-
Solidsolution
2212±662
405
4
>29
(estim
ated)
14.51±0.29
>30
(estim
ated)
Table4.3.:EnhancedbioavailabilityanddrugϐluxofSoluplus
R/drugform
ulations(invivon=5;m
ean±SD;invitron=3–6;m
ean±SD)
38
CHAPTER 4. SOLUPLUS R AS AN EFFECTIVE ABSORPTION ENHANCER OF POORLY
SOLUBLE DRUGS IN VITRO AND IN VIVO
Figure 4.6.: Effect of Soluplus R on itraconazole ϐlux across Caco-2 monolayer and on AUC
in animal study (n=3 for in vitro data, n=5 for in vivo data; mean ± SD)
4.3.4. Dialysis
Equilibrium dialysis experiments were conducted to evaluate drug interactionswith Solu-
plus R. As indicated by donor/acceptor ratios > 1 (Table 4.4) danazol, fenoϐibrate and itra-
conazole were retained on the donor side of the dialysis system, i.e. the side to which
Soluplus R was applied, indicating complex formation or binding of drug to Soluplus R. In
contrast, for fenoϐibric acid, a donor/acceptor ratio nearby 1 was reached for 0.2% TPGS
as acceptor medium. This equal distribution to both sides of the system proves that no
stable complex is formed with fenoϐibric acid. Mass balance of drug amounts on both
sides of the dialysis system afforded recovery rates of nearby 100% (data not shown).
The donor/acceptor ratios were highest for itraconazole, followed by danazol and lowest
for fenoϐibrate. An inϐluence of the acceptor medium used was only detectable for fenoϐi-
brate and danazol which signiϐicantly increased when Vitamin E TPGS (0.2% as used in
the transport experiments) was replaced by 1% bovine serum albumine (BSA) to solu-
bilize the drug in the acceptor compartment. In case of fenoϐibric acid, the equilibrium
shifted to the acceptor side when BSA was added, probably by a bigger binding strength
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donor/acceptor (KRB + 1% BSA) donor/acceptor (KRB + 0.2% TPGS)
Danazol 9.88 ± 0.39 3.68 ± 0.34
Fenoϐibrate 4.91 ± 0.16 1.43 ± 0.17
Fenoϐibric acid 0.43 ± 0.01 1.01 ± 0.02
Itraconazole 16.35 ± 0.67 21.02 ± 5.9
Table 4.4.: Results from dialysis experiments of a physical mixture of 0.5% Soluplus R and
the respective drug. Data given as donor/acceptor ratio (n=5; mean ± SD)
of fenoϐibric acid to the protein than to Soluplus R. However, the order of the strength of
binding remained the same for both acceptor media (itraconazole > danazol > fenoϐibrate
> fenoϐibric acid).
4.4. Discussion
As shown in many studies, the Caco-2 monolayer model is an useful tool to predict drug
permeation in the human intestine [66, 74, 102]. As such, the model has not only been
used to investigate the permeability of pure drugs in solution, but also of more complex
systems studying the effect of solubility enhancers and other excipients on drug trans-
port rates or even studying novel formulations such as nanoparticles or solid solutions
[109, 102]. In the present study we looked at the effect of Soluplus R on intestinal absorp-
tion of the poorly soluble, highly permeable BCS class II compounds itraconazole, fenoϐi-
brate and danazol. The novel excipient Soluplus R not only provides solubility enhance-
ment by its amphiphilic structure but also offers the feasibility of forming solid solutions
with poorly soluble drugs. Thus, both physical mixtures of drug and Soluplus R and solid
solutions with respective drug/excipient ratios were investigated. As a validation of the in
vitro experiments, the different formulations were also orally applied to beagle dogs for in
vivomonitoring of drug bioavailability via plasma levels.
For all three drugs the highest permeation over the Caco-2monolayer was, for fenoϐibrate
besides the physical mixture, realized by the solid solution. For danazol and itraconazole
no or only limited effectiveness of a physicalmixture of drug and excipient on drug perme-
ation was detected. Although the drug solubility was increased in presence of Soluplus R
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(Table 4.1), drug permeation remained on a low level, comparable to the pure drug. The
superior bioavailability from the solid solution and the poor effect of the physical mixture
predicted in the Caco-2 model was conϐirmed in the in vivo experiments. In particular,
the magnitude of absorption change correlated in both setups when drug ϐlux was com-
pared with AUC. The failure of Soluplus R as a mere solubility enhancer in the physical
mixture suggests that the amorphous state of the drug in the solid solution plays a crucial
role for drug dissolution and permeation. Supersaturated drug solutions are only realized
from the solid solutions allowing for steeper concentration gradient and higher drug ϐlux
across the epithelial barrier. Tight junction integrity and epithelial barrier properties are
not affected by Soluplus R as TEER values stayed constant throughout the course of the
experiments (see Appendix B for additional data) and no increase in transport of para-
cellulary transported marker dye ϐluorescein sodium could be observed in control exper-
iments (see Chapter 6 for ϐluorescein transport experiments). Furthermore, both danazol
and itraconazole showed strong binding to Soluplus R in equilibriumdialysis experiments,
indicating that increased solubility in the presence of Soluplus R is compensated by high
afϐinity complex formation to the non-permeable excipient.
In contrast, for fenoϐibrate, Soluplus R in a physical mixture was as effective as the solid
solution (in animal) and also signiϐicantly superior to the pure drug in increasing in vitro
transport. Thus, for some drugs already a physical mixture could be an alternative for a
solid solution, reducing production costs and avoiding stability issues as might be faced
with heat-sensitive and polymorphous drugs. The mechanistic basis for the observed dif-
ferences between danazol and itraconazole on one hand and fenoϐibrate on the other hand
are not completely understood yet but might be connected to the low melting point of
fenoϐibrate compared to the other tested drugs (Table 4.1, [110]). Chu and Yalkowsky in-
troduced a melting point based absorption potential (MPbAP) which correlates the melt-
ing point to the absorbed fraction of BCS class II/IV drugs. Based on the MPbAP, a lower
melting point leads to a higher absorption. Accordingly, fenoϐibrate shows higher in vitro
and in vivo absorption than danazol and itraconazole, especially in case of the physical
mixture.
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A discrepancy exists between fenoϐibrate in vitro and in vivo datawith regards to the phys-
ical mixture: in animal studies the physical mixture performed equal to the solid solution,
while in the in vitro experiments the observed drug ϐlux was in between the solid solution
and the pure drug, the observed increase in drug permeation rate being about 2-fold lower
than the in vivo impact. This may be attributed to in vivo interaction of the drug and/or
Soluplus R with the intestinal ϐluids which contain bile salts and phospholipids leading to
the formation ofmixedmicelles [111, 112]. The impact of dissolution and transportmedia
composition for fenoϐibrate was previously conϐirmed by in vitro dissolution and perme-
ation experiments using fasted or fed state simulated intestinal ϐluids (FaSSIF; FeSSIF). It
was shown that dissolution and permeation rate is improved by these media [97]. There-
fore, it is probable that for the physical mixture of fenoϐibrate, Soluplus R and the micelles
present in the intestine show a synergistic effect on drug absorption in vivo. Although food
effects are also reported for danazol and itraconazole [113, 114, 115], in our study no ef-
fect of the physical mixture was shown in vitro and in vivo. We suggest that danazol and
itraconazole are already well solubilized by Soluplus R micelles and show strong binding
to the excipient. Thus, the mixed micelles present in vivo do not have an additional effect.
The differences in binding afϐinity between the three compounds are not yet mechanis-
tically understood, although it seems that higher lipophilicity is associated with stronger
binding to the excipient structures. Furthermore, the pHmay play a role in the differences
between in vivo and in vitro absorption. While cell culture experiments were performed
at a constant pH of 7.4, in vivo the formulations occur a pH gradient which will especially
affect the ionizable drugs itraconazole and fenoϐibric acid.
Additionally, it was shown that fenoϐibrate mainly appears as fenoϐibric acid on basolat-
eral side. Samples drawn from the apical side of the Transwell system also show a sig-
niϐicant amount of fenoϐibric acid. It is therefore probable, that solubilized fenoϐibrate
is hydrolyzed by enzymes located on apical side of the Caco-2 cells and that mainly the
metabolite fenoϐibric acid diffuses across the cell monolayer. As fenoϐibric acid is less
lipophilic than fenoϐibrate and provides a much higher aqueous solubility, it provides a
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Figure 4.7.: Fenoϐibrate ϐlux across Caco-2 monolayers at 4 C. Results expressed as
fenoϐibric acid (n=3; mean ± SD)
reduced binding to Soluplus R as proven by equilibrium dialysis (Table 4.4). Also the ef-
fectiveness of the physical mixture might be explained by that fact: an extensive super-
saturation of the drug provided by a solid solution is not necessary, since the transport
is controlled by the hydrolysis to fenoϐibric acid and its diffusion. Further experiments
conducted at 4 C (reduced enzyme activity) conϐirmed this hypothesis. The drug ϐlux and
also the amount of fenoϐibric acid on apical side were many fold lower under these condi-
tions (Figure 4.7).
The same mechanism is as well suitable for the in vivo situation as the intestinal mem-
brane also provides a high variety of hydrolyzing enzymes and the bioavailable form of
fenoϐibrate detected in blood is also fenoϐibric acid [116].
For itraconazole, HPβCD was added in a concentration of 1% (w/w) to the acceptor me-
dium. Although Mellaerts et al. considered an addition of 0.2% Vitamin E TPGS (as used
for danazol and fenoϐibrate) with Caco-2 monolayers as equivalent to rat plasma as ac-
ceptor medium for itraconazole transport experiments [106], we changed the constitu-
tion of the acceptor medium as Vitamin E TPGS 1000 is known to inhibit the P-gp efϐlux
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system [117, 30]. Since itraconazole is a substrate of P-gp, efϐlux inhibition would likely
have altered drug transport in our experiments [118]. In contrast HPβCD, has no effect on
P-gp efϐlux, drug permeability and monolayer integrity in Caco-2 transport experiments
[119, 120]. However, an intrinsic P-gp inhibition afforded by Soluplus R cannot be ex-
cluded neither in vivo nor in vitro and may account for some of the observed increase in
itraconazole absorption. Besides Vitamin E TPGS, P-gp inhibitionwas already reported for
a number of non-ionic surface-active excipients such as Tween 80, Cremophor EL and sev-
eral Pluronic block copolymers [121, 30]. A possible P-gp modulating effect of Soluplus R
is still under investigation.
This study clearly proves the potential of Soluplus R to improve oral bioavailability. For
danazol the observed bioavailability enhancement (15-fold increased AUC) was slightly
lower compared to a 16-fold or 20-fold increased AUC (compared to the pure drug) in
beagle dogs which was reached using nanoparticulate or cyclodextrin formulations, re-
spectively [92]. However, these formulation approaches never reached the market. Also
conventional hard capsules of crystalline danazol (Danacrine R) are mostly off-market
as Gonadotropin-releasing hormone agonists offer a better beneϐit-to-risk proϐile for the
treatment of endometriosis. In the case of fenoϐibrate, the marketed nanoparticulate for-
mulationTriCor R/Lipidil R ONEenableda2.8-fold increasedAUC (compared tobulkdrug)
in Wistar rats [97], while Soluplus R formulations showed an about 5-fold increased AUC
compared to the pure drug in beagle dogs. However, inter-species differences might play
an important role hereby and prohibit a direct comparison. Therefore, a side-by-side com-
parison may be included in further studies. For itraconazole, Yi et al. observed an AUC
of 9,400 ± 2.5 ng  h  ml-1 after oral application of the commercialized itraconazole-
HPβCD solution (Sporanox R oral solution) in a dose of 7.5 mg/kg to fasted beagle dogs
[89]. Although this AUC is about 4-fold higher compared to the AUC of the Soluplus R solid
solution, a future direct comparison under identical experimental conditions may further
elucidate if the commercial product is really superior to the Soluplus R solid solution.
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4.5. Conclusion
Soluplus R effectively enhanced the absorption of itraconazole, danazol and fenoϐibrate
through the intestinal barrier if applied as solid solution. This could be shown in the
Caco-2 in vitro system as well as in beagle dogs in vivo. For fenoϐibrate additionally the
physical mixture of the test compound with Soluplus R was able to increase absorption
and bioavailability in vivo and in vitro. The current work underlines the potential of the
Caco-2 monolayer model as an excellent predictive tool for intestinal absorption behav-
ior, not only for pure drugs but also for more complex drug-excipient formulations e.g. as
solid solutions. As demonstrated for fenoϐibrate, we were able to distinguish in vitro be-
tween drugs forwhich the use of a solid solution is effective and drugs forwhich a physical
mixture is sufϐicient to achieve a good oral bioavailability in accordance to in vivo tests in
beagle dogs. However, for a better understanding of the absorption behavior in vivo and
in vitro, further studies investigating the mechanism of drug liberation and transport in
the presence of Soluplus R are needed.
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5. Inhibition of P-glycoprotein and/or
trypsin by Soluplus R
Parts of this chapter will be published as journal article :
InhibitionofP-glycoproteinbySoluplus R Michael Linn, DejanDjuric, KarlKolter, Claus-
Michael Lehr, Eva-Maria Collnot
Pharmaceutical Research in submission
Abstract
Purpose. To investigate whether polyvinyl caprolactam-polyvinyl acetate-polyethylene
glycol graft copolymer (Soluplus R), a novel solubility enhancer, inhibits the human efϐlux
transporter P-glycoprotein (P-gp). Additionally, Soluplus R was tested for a possible inhi-
bition of the digestive protease trypsin.
Methods. Inhibition of P-gp was investigated by two methods. First, bi-directional trans-
port experiments across Caco-2monolayers, grown on commercial Transwell ϐilters, were
performed. Rhodamine 123 (RHO) and digoxin (DIG) were used as P-gp substrates. Sec-
ond, we investigated the uptake of the ϐluorescent P-gp substrates rhodamine 123 and
LDS 751 into P-gp transfectedMDCK II cells and comparedwith uptake into non-P-gp con-
taining wild type cells. A possible trypsin inhibition was evaluated by investigating the
cleavage of the marker substrate N--benzoyl arginine ethyl ester (BAEE) in Soluplus R
solutions.
Results. For both tested substrates the basolateral to apical transport was strongly de-
creased by increasing Soluplus R concentrations. Apical to basolateral diffusion was also
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reducedby the excipient, as a result of binding of the substrates to Soluplus R, prohibitiung
the calculation of efϐlux ratios. Uptake experiments into MDCK II cells allowed the deter-
mination of net efϐlux of the unbound substrate fraction. In the presence of higher con-
centrations of Soluplus R an increased net uptake into MDCK-MDR1 cells was observed,
further proving P-gp inhibition by Soluplus R. Only a slight inhibition of trypsin was found
at a concentration of 10% Soluplus R.
Conclusions. It was shown that Soluplus R inhibits P-gp mediated efϐlux with an EC50
around 3–7mg/ml. In the design of novel Soluplus R containing formulations the likeli-
hood of reaching these concentrations in vivo has to be considered. No interference of
Soluplus R with the protease trypsin was found.
5.1. Introduction
P-glycoprotein (P-gp) is a 170 kDa transmembraneous protein of the large superfamily of
ATP-binding cassette (ABC) transporters [13, 20]. As it plays an important role in mul-
tidrug resistance it is also known as multidrug resistance protein 1 (MDR1). P-gp is an
active transporter which mediates the efϐlux of several drugs under consumption of ATP.
Human P-gp is strongly expressed in all major epithelia such as kidney, liver, capillary en-
dothelium and the intestinal epithelium [22]. It is responsible for the efϐlux of drugs at
the blood-brain barrier and even more important: the intestinal barrier [23, 24]. Thus,
P-gp is able to hinder the resorption of drugs, resulting in a reduced oral bioavailability
[25]. Due to its broad substrate speciϐicity, it transports drugs of diverse classes, such
as several chemotherapeutics, antibiotics, antifungals, glucocorticoids, HIV-1 protease in-
hibitors and cardiac glycosides.
As a not much smaller group of xenobiotics is able to inhibit or induce human P-gp, this
efϐlux transporter bears a high potential for drug-drug and also drug-excipient interac-
tions [27, 28]. Well-described interactions are those of the cardiac glycoside digoxin with
the drugs verapamil or ketoconazole and with the natural products of St. John’s wort or
grapefruit [123, 124, 125].
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Besides drugs and natural products, excipients are potential inhibitors of human P-gp.
MDR1 inhibition was shown for surfactants, natural and synthetic polymers [29, 30, 31].
Drug-excipient interactions do not only bear the risk of adverse side effect, butmay also be
desired to enhance bioavailability of P-gp substrates [126, 127, 128, 129]. In this context,
the non-ionic surfactant Vitamin E TPGSwas used in the formulation of theHIV-1 protease
inhibitor and P-gp substrate amprenavir and commercialized as Agenerase R oral solution
[32].
In the present study a possible P-gp inhibition by a novel solubility enhancer (Soluplus R)
was investigated. Soluplus R (polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol
graft copolymer) is a surfactant and allows an effective solubility enhancement of poorly
aqueous soluble drugs, both by its surface active properties and by its ability to form
solid solutions (see Chapter 4). Thereby, it was shown that Soluplus R increases the oral
bioavailability of lipophilic drugs, such as itraconazole or fenoϐibrate(see Chapter 4; [84]).
As many poorly soluble drugs are at the same time P-gp substrates, an inhibition of this
transporter by Soluplus R may also affect drug resorption through the intestinal barrier.
To determine a possible interaction of this novel excipient with MDR1, two cell culture
modelswere used. First transport of the two P-gpmodel substrates rhodamine 123 (RHO)
and digoxin (DIG) was measured in the well-characterized Caco-2 cell line, a widely used
model of the intestinal barrier [65, 130]. As Caco-2 cells extensively express P-gp, this
model is accepted for the investigation of active efϐlux across the cell monolayer by bi-
directional transport experiments [131, 132]. Secondly, Madin Darby canine kidney
(MDCK II) cells were used. While the wild type hardly expresses P-gp, it is possible to
transfect this cell line with MDR1 [133, 134, 135]. Therefore, it is possible to assess the
passive permeability of a drug in the parent cells in the absence or presence of Soluplus R
and then determine active P-gp mediated efϐlux as the difference in drug uptake between
wild type and transfected cells.
Another active protein that might reduce the bioavailability of orally applied drugs is the
serine protease trypsin. Trypsin is produced in the pancreas and secreted into the duode-
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num. It is active there and hydrolyzes peptides into amino acids. Therefore, trypsin is one
main barrier for the oral application of peptide drugs, such as insulin [136, 137]. Several
compoundswere shown to have trypsin inhibiting activity, such as Bowman-Birk inhibitor
[138, 139], soybean ingredients or ϐlavonoids [140]. Some excipients were also shown to
inhibit trypsin, e.g. poly(acrylate) derivatives [141]. Therefore, the novel solubilizing ex-
cipient Soluplus R was tested if it can act as potential trypsin inhibitor and if it hence may
be applied for peptide drug delivery.
5.2. Materials and Methods
5.2.1. Chemicals
Soluplus R was provided by BASF SE (Ludwigshafen, Germany). Fetal bovine serum was
fromPAN-Biotech GmbH (Aidenbach, Germany). Dulbecco’smodiϐied Eagle’smediumand
non-essential amino acids were from PAA Laboratories GmbH (Pasching, Austria). Per-
meable ϐilter inserts of type Transwell 3460 were supplied by Corning Incorporated Life
Science (Lowell MA, USA). 3[H]-Digoxin (40 Ci/mmol) and Ultima Gold scintillation ϐluid
were obtained from Perkin Elmer (Rodgau, Germany). Bovine serum albumin, digoxin,
rhodamine 123, LDS751, Hoechst 33342 and all other chemicals were purchased from
Sigma-Aldrich (St. Louis, MO, USA).
5.2.2. Cell culture
Caco-2 cells of clone C2BBe1 from American Type Culture Collection (Manassas, CA, USA)
were grown under conditions at 37 C in an atmosphere of 5% CO2 and 80% relative hu-
midity. Dulbecco’s modiϐied Eagle’s medium supplemented with 10% fetal bovine serum
and 1%non-essential amino acidswas used as cell culturemedium. Mediumwas changed
every 2–3 days. Cells were passaged every week at a conϐluency of approx. 90%. For
transport experiments, cells of passage64–77were seededat adensity of 66,000 cells/cm2
on Transwell ϐilter inserts (0.4 µm pore size, 1.12 cm2). After 21 days in culture, cells
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were used for transport experiments if the transepithelial electrical resistance (TEER)was
above 500 
 cm2.
P-gp expressing MDCK II cells (MDCK-MDR1) and the respective maternal wild type cell
line (MDCK-wt)were kindly providedbyProf. Schinkel (Netherlands Cancer Institute, Am-
sterdam, Netherlands). Both cell lines were cultured as described above for Caco-2 cells.
The cell culturemedium consisted of DMEM+ 10% FBSwithout addition of non-essential
amino acids. For uptake experiments cells were seeded at a density of 20,000 cells per
well in 96-well cell culture plates and grown to conϐluency for 7 days. Cells were used 4–7
passages after receiving from Prof. Schinkel.
5.2.3. Bi-directional transport experiments
Krebs Ringer buffer (KRB)was used as assay buffer. KRB contains 114.2mMNaCl, 3.0mM
KCl, 4.0mM d-glucose, 1.4 mMCaCl2, 2.6mM MgCl2, and 10.0mM HEPES. By addition of
NaOH the buffer was adjusted to a ϐinal pH of 7.4. For digoxin transport studies addition-
ally 1% BSA was added to avoid adhesion to plastic material.
In this assay the transport of the P-gp substrates RHO and DIG across the Caco-2 mono-
layerwas investigated in both possible directions: apical to basolateral (AB) transport and
basolateral to apical (BA) transport. Afterwashing twicewith prewarmedKRB, themono-
layers were pre-incubated under cell culture conditions for 1.0 h with prewarmed assay
buffer with or without Soluplus R in the respective concentration to be tested. Buffer con-
taining Soluplus R was only applied on apical side. As positive control a solution of Cy-
closporine A (10 µM) was used and as well applied on the apical side of the system. Af-
ter pre-incubation, solutions of 10 µM RHO or 1 µM DIG (spiked by 0.1 nM 3[H]-DIG) in
KRB were applied on the respective donor side. The system was agitated at 100 ± 20 rpm
throughout the experiment on an orbital shaker in a cell culture incubator. At regular time-
points up to 240minutes samples of 100 µl (RHO) or 200 µl (DIG) were drawn at regular
timepoints from the receiver compartment and the volume lost by sampling was replaced
with fresh pre-warmed buffer.
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RHOwas quantiϐied by measuring the ϐluorescence at an excitation wavelength of 485 nm
with an emission wavelength of 530 nm, using a 96well plate reader (Tecan inϐinite 200,
Tecan Group Ltd, Männedorf, Switzerland). To avoid bias by signal quenching separate
calibration curves were used for each tested Soluplus R concentration.
Samples of DIG were diluted by 2.0ml of scintillation ϐluid and afterwards radioactivity
wasmeasured by liquid scintillation counting in a TriCarb 2100TR analyzer (Packard Bio-
Science, Meriden, CT, USA).
The apparent permeability was calculated by the formula:
Papp =
dc
dt
 1
c0
 1
A
(5.1)
whereas dc/dt indicates the slope of the linear permeation curve, c0 indicates the initial
substrate concentration and A the area of the cell monolayer.
5.2.4. Dialysis
To investigate the binding of the model substrate RHO to Soluplus R equilibrium dialysis
was performed using a DIANORM R apparatus (identical to DIALYZER by Harvard Appa-
ratus, Holliston, MA, USA). The donor chambers of the system were ϐilled with 2ml of a
solution of 10 µMRHO and Soluplus R in KRB. The acceptor sides were ϐilledwith an equal
volume of pure KRB. A cellulose membrane (Harvard Apparatus, Holliston, MA, USA) with
amolecular cutoff of 10 kDa separated the two chambers. After one hour dialysis at a rota-
tion speed of 20rpm, the chamberswere emptied and RHOwas quantiϐied by ϐluorometric
measurements as described above. Additionally, the experiment was performed with an
inversed setup. Therefore, Soluplus R solutions functioned as acceptormedia and a 10 µM
RHO solution in KRB without Soluplus R acted as donor. As indicator for drug binding the
ratio of RHO between donor and acceptor was calculated (D/A ratio).
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5.2.5. MDCK II uptake assay
For uptake experiments MDCK II cells, of wild type or transfectedwithMDR1 respectively,
werewashed twicewith pre-warmedKRB. Afterwards 200 µl of a substrate solution (RHO:
25 µM, LDS751: 50 µM)with orwithout Soluplus R inKRBwas added to eachwell and cells
weremaintained at 37 C in an incubator. Cellswere agitated at a speed of 100 ± 20 rpmon
an orbital shaker. After two hours incubation time cells werewashed three timeswith ice-
cold KRB to stop active transport. Afterwards cells were lysed by a 200 µl of a solution of
1%Triton X in KRB and total ϐluorescence in the lysatewasmeasured. RHOwas quantϐied
as discussed above while LDS 751 was excited at 543 nm and measured at 712 nm, the
detection wavelength for LDS 751 bound to cellular DNA.
The amount of substrate that was pumped out of the cells by P-gp was calculated by the
formula:
Amounteffluxed = nWT   nMDR1 (5.2)
where nWT indicates the quantity of substrate taken up in wild type cells, whereas nMDR1
represents the respective amount in MDR1 transfected cells.
5.2.6. Trypsin inhibition assay
For evaluating the effect of Soluplus R, the cleavage of the marker substrate N--benzoyl-
L-arginine ethyl ester (BAEE) to N--benzoyl-L-arginine (BA)was studied (Figure 5.1). As
buffer for this assay served a solution of 50mM MES/KOH pH 6.7, supplied with 250mM
mannitol (assay buffer). A solution 1.5mM BAEE  Soluplus R was incubated with 30 IU
trypsin at 37 C for 40min. After the incubation time hydrolysis was stopped by the addi-
tion of 1M hydrochloric acid. As positive control a solution of soybean trypsin inhibitor in
assay buffer was used.
The amount of BAwas analyzed by HPLC, injecting a sample volume of 20 µl on a reversed
phase column [LiChroCART 125-4 LiChrospher 100 RP18 (5 µM) by Merck KGaA (Darm-
stadt, Germany)]. As mobile phase a mixture of 86% 10mM ammonium acetate pH 4.2
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Figure 5.1.: Trypsin hydrolyzes N--benzoyl-L-arginine ethyl ester (BAEE) to N--
benzoyl-L-arginine (BA)
and 14%methanol was used. BAwas detected absorptiometric at a detectionwavelength
of 253 nm. The detected amount of formed BA was relied to the amount found for the
negative control (assay buffer).
5.3. Results
5.3.1. Caco-2 transport assay
To examine, whether P-gp is inhibited by Soluplus R the transport of the P-gp substrates
RHO and DIG across Caco-2 monolayers was determined. To allow for comparison be-
tween different experiment with slight variations in P-gp expression and thus transport
rates data for apparent permeability (Papp values) was normalized to the respective con-
trol (KRB w/o inhibitor).
Application of Soluplus R on apical side lead to a reduced secretory transport of RHO from
basolateral to apical side (Figure 5.2 A). P-gpmediated basolateral to apical transport was
reduced to 54.3 ± 3.6%by an excipient concentration of 25mg/ml. As shown in Figure 5.3
A, basolateral to apical transport was also reduced in a concentration dependent manner
with anonset at a Soluplus R concentrationof 1mg/ml. AnEC50 valueof 3.14 ± 1.13mg/ml
was calculated by a four parameter logistic ϐit of the curve. The positive control using
10 µM CysA as a potent P-gp inhibitor reduced BA transport even further to a level of
31.9% compared to control.
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Figure 5.2.: Rhodamine 123 transport across Caco-2 monolayers. A: Active basolateral to
apical transport. B: Passive apical to basolateral transport (n=3; mean SD)
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Figure 5.3.: RHO transport across Caco-2 cells. Papp values normalized to the respective
control. A: Basolateral to apical. Fitted curve: R2=0.9105. B: Apical to basolat-
eral transport. (n=3–9; mean SD)
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Figure 5.4.: Digoxin transport across Caco-2 cells. Papp values for active basolateral
to apical transport are normalized to the respective control. Fitted curve:
R2=0.9871. (n=3–9; mean SD)
RHO transport from apical to basolateral side also showed a concentration dependent de-
crease by apical application of Soluplus R (Figure 5.2 B). At a concentration of 25mg/ml,
apparent permeability of RHOwas reduced to 48.3 ± 8.3% of the control (Figure 5.3 B). In
contrast, by application of CysA to the apical side, AB transport was increased to 175% of
the control.
As both AB and BA transport of RHO were reduced in the presence of Soluplus R, efϐlux
ratio remainedmainly unchanged at all tested concentrations, while CysA control showed
an efϐlux ratio of 1.42. As in this experiment Soluplus R and the substrate were applied in
the same compartment, an interaction of Soluplus R and RHO can be assumed. If no inter-
action takes place, an increased AB transport would be expected for P-gp inhibitors.
Transport of DIG showed similar behavior. By increasing Soluplus R concentration, the
apparent permeability of active basolateral to apical transport was reduced (Figure 5.4).
By an excipient concentration of 100mg/ml the permeability was reduced to 17.3 ± 1.9%
of the inhibitor-free control. As for RHO, the reduction in DIG permeability was concen-
tration dependent, however, EC50 value calculated was shifted to higher Soluplus R con-
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Figure 5.5.: Equilibrium dialysis of Soluplus R/RHO formulations. A:“Standard” setup,
Soluplus R and RHO on donor side. B: “Inversed” setup, Soluplus R applied
to acceptor side (n=5; mean SD)
centrations (EC50 = 43.68 ± 11.96mg/ml).
5.3.2. Dialysis
Equilibriumdialysis was performed to investigate a possible binding of Soluplus R to RHO,
thereby explaining the reduced A to B transport in Caco-2 experiments. Indeed, if RHO
and Soluplus R were applied in the same compartment, RHO was retained from diffusion
to the acceptor compartment. As shown in Figure 5.5 A, increasing Soluplus R concentra-
tions lead to higher donor/acceptor ratios. At an excipient concentration of 25mg/ml, the
concentration of RHO in the donor compartmentwas 10.7-fold higher than in the acceptor
compartment. As the control without Soluplus R showed a ratio of about 1, it was proven
that equilibrium was reached after the used dialysis time.
Dialysis with an inversed setup showed that Soluplus R, if applied on acceptor side, pulled
RHO to this side. This pull-effect additionally afϐirms the binding of RHO to Soluplus Rwith
a donor/acceptor ratio of 0.11 at 25mg/ml Soluplus R (Figure 5.5 B).
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Figure 5.6.: Soluplus R concentration dependent uptake of RHO (A) and LDS 751 (B) into
MDCK-wt and MDCK-MDR1 cells.(n=5–6; mean SD)
5.3.3. Uptake into MDCK II cells
The uptake of RHO and LDS751 into MDR1-tranfected and wild type MDCK II cells was
tested. As shown in Figure 5.6, both P-gp substrates showed a Soluplus R concentration
dependent decreased uptake into both cell lines. For both tested substrates the uptake
into wild type cells was signiϐicantly higher compared to MDR1 transfected cells, as ex-
pected by P-gp efϐlux activity.
To determine the P-gp activity, the efϐluxed amount (Equation 5.2) was calculated as the
difference between amount absorbed into wild type cells and transfectants. Hence, any
possible reduction in free drug concentration in the presence of Soluplus R due to binding
to the excipientwas taken into account. For bothRHOandLDS751 thenet efϐluxed amount
wasdecreasedby increasing Soluplus R concentration (Figure5.7). For Soluplus R concen-
trations between 0.01 and 1mg/ml (RHO) or 0.01 and 5mg/ml (LDS751) an increased
efϐlux was observed. Positive control experiments using 20 µM CysA as inhibitor demon-
strated a 3-fold (RHO) and 1.5-fold (LDS751) increased uptake of RHO/LDS751 into the
wild type cells. In MDCK II-MDR1 cells the uptake was increased by 8.6-fold and 2.3-fold
for RHO and LDS 751 in the positive control, respectively.
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Figure 5.7.: Efϐluxed amount of P-gp substrates RHO and LDS 751 fromMDCK II cells, nor-
malized to the respective control (n=5–6; mean values).
5.3.4. Trypsin inhibition
As shown in Figure 5.8, only a very slight inhibition of trypsin by Soluplus R could be de-
tected. A slight concentration dependent decrease of themetabolized amount of BAEEwas
found. However, at a Soluplus R concentration of 10% still 87.8% of the control value for
BA could be found. For lower concentrations, a trypsin activity of more than 90% was
detected. Therefore, it can be assumed that Soluplus R affects trypsin only on a low level.
5.4. Discussion
In recent years, it was shown that many polymeric pharmaceutical excipients inhibit hu-
man P-gp. The interaction of an excipient with human efϐlux transporters bears risks of
drug-formulation interactions but at the same time offers chances to enhance bioavail-
ability of substrates in a local and controlled manner. Therefore, it is evident that a novel
compound, such as Soluplus R, should be evaluated for a possible P-gp inhibition. In this
work, it was shown that the novel solubilizer Soluplus R, in high concentrations, inhibits
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Figure 5.8.: Formation of N--benzoyl-L-arginine under the inϐluence of Soluplus R. Only
slight trypsin inhibition can be detected (n=3–5; mean SD)
human P-glycoprotein:
Bi-directional transport experiments across Caco-2 cells showed a decreased Papp by in-
creasing Soluplus R concentrations in both transport directions (AB and BA) for two dif-
ferent P-gp model substrates, RHO and DIG. Many studies regarding P-gp inhibition in the
Caco-2 model are using the efϐlux ratio, calculated by the formula
Effluxratio(ER) =
Papp(BA)
Papp(AB)
(5.3)
, asmeasure for P-gp activity [142, 143]. When calculating efϐlux ratios for both substances
in our study no signiϐicant change in dependence of Soluplus R concentration is observed.
Onemight therefore conclude that there is nomodulation of P-gp activity afforded by Solu-
plus R. However, using the efϐlux ratio to assess P-gp inhibition might is often misleading,
e.g. for substrateswith a high passive permeability [144, 145, 146] or if the AB transport is
too low for reliable calculations [147]. In our experiment to distinct phenomena account
for the respective reduction in transport. For apical to basolateral transport the observed
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reduction is associated to a binding of the model drug to the polymeric excipient, as both
compounds are placed in the same compartment for this experimental setup. Such a bind-
ing of moderately to highly lipophilic compounds was previously observed for BCS class II
drugs itraconazole, danazol and fenoϐibrate (see Chapter 4 & 6). For RHO, we could show
the binding to Soluplus R in equilibrium dialysis experiments: Donor/acceptor ratios up
to 10.7were observed at the concentrations used in the transport studies. The entrapment
in the drug-excipient complex limits the free drug amount available for diffusion and re-
duces the ϐlux across the monolayer. A similar effect was recognized by Zuo et al. (2000)
in the case of hydroxypropyl-ß-cyclodextrin, which forms highly stable complexes with
ϐlutamide, hindering its diffusion across Caco-2 cells in higher concentrations [122]. In
contrast, if placed in the opposite compartment to RHO, Soluplus R exhibits a pull effect
in equilibrium dialysis studies. Thus, a higher drug ϐlux across the monolayer would be
expected in the presence of Soluplus R on the apical side, if RHO or DIG transport was only
mediated by passive diffusion. Instead, the opposite effect is observed and the reduction
of BA transport may therefore be associated to P-gp efϐlux inhibition.
To test this hypothesis, uptake experiments were conducted in MDCK II cells, comparing
accumulation in the cells inwild type cellswith low inherent efϐlux activity and in transfec-
tants overexpressing human P-gp. This setup allows the calculation of net efϐlux mediated
by P-gp, as both cell lines should have similar passive permeability for the model sub-
strates and thus hindering effect of Soluplus R-drug complex formation can be accounted
for by substracting this amount of drug diffused. It has to be noted, that the incubation of
MDCK wild type cells with CysA as positive control also increased the ϐluorescent model
compounds uptake. Therefore, a certain efϐlux activity can be assumed for the wild type
cells, likely due to canine efϐlux transporters with overlapping substrate speciϐity to hu-
man P-gp. The incubation of wild type MDCK II cells with Soluplus R also resulted in an
increaseduptake into these cells at lowSoluplus R concentrations. Thus, an elevated efϐlux
was calculated for these Soluplus R levels. However, at high Soluplus R concentrations the
inhibition of human P-gp in MDCK II-MDR1 cells becomes evident.
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An EC50 value of 6.91 ± 2.2mg/ml was calculated for RHO which is in the same order as
calculated for RHO efϐlux inhibition in Caco-2 BA transport experiments (3.15mg/ml). For
digoxin, the inhibition curve is shifted to higher concentrations resulting in a 13.8-fold in-
creased EC50 value. A possible reason for this difference might be an induction of MDR1
in Caco-2 cells during the incubation time by the used substrate [148, 149] or the pres-
ence of distinct binding sited for different P-gp substrates with distinct inhibition kinetics
[150, 151]. Another reasonmight be the efϐlux pathway of RHOwhich requires a saturable
inϐlux through the basolateral membrane to be efϐluxed by P-gp [152]. Furthermore, mul-
tidrug related protein 2 (MRP2), which is also present in Caco-2 cells, is known to efϐlux
RHO and DIG [153, 154, 155]. Therefore, an interaction of Soluplus R with MRP2, might
play a role in the observed differences between the two substrates.
In conclusion, for both test systems a reducedMDR1 activity in the presence of higher con-
centrations of Soluplus R was shown. However, an exact calculation of an EC50 value was
not possible, due to differences in the test systems and between the used substrates. Also
an extension of the study to even higher Soluplus R concentrations to establish a better ϐit
of the inhibition curve for digoxin was not possible, as Soluplus R solubility is limited to
100 mg/ml.
In comparison to other P-gp modulating excipients, the potency of Soluplus R is moder-
ate. EC50 values for Vitamin E TPGS, Pluronic F68 or Pluronic P85 were found to be one
to two orders of magnitude lower compared to Soluplus R [31, 156]. It is questionable, if
the necessary inhibitory concentrations observed in this study would be reached in the
human intestine with actual Soluplus R containing formulations. Assuming an EC50 value
of 3.15mg/ml (RHO, Caco-2), the corresponding dose, orally applied with 250ml water,
would be 787.5mg. This amount of a single excipient is not likely to be formulated in a
single oral dose as drug and co-excipients would be present even in the preparation of
solid solution based pellet formulations. However, as this dose might be reached by con-
comitant application of more than one tablet, a potential for drug-excipient interactions
can’t be completely disregarded. Even though, the excipient is not only distributed to the
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ingested volume, but also to liquids secreted into the human intestine. Taken into account
that totally about 6 litres of ϐluids are secreted per day, the dose needed for an effect on
human P-gp would be many fold higher [4].
An inhibition of the protease trypsin was only found for very high Soluplus R concentra-
tions. A concentration of 10%ormore Soluplus R is usually not likely to be reached in vivo.
Therefore, Soluplus R is probably no possible candidate for enhancing the oral bioavail-
ability of peptide drugs. However, by these results also adverse side effects of trypsin
inhibitors, such as a disturbed digestion of nutritive proteins or an increased protease se-
cretion as feed-back regulation can be excluded [157, 137].
5.5. Conclusion
The novel solubility enhancer Soluplus R was tested for its inhibitory potential on human
P-glycoprotein and trypsin. Our studies clearly prove an effect of the excipient on P-gp by
increasing concentrations. As Soluplus R binds to the used substrates, an assessment of
P-gp activity by regarding absorptive (AB) transport or calculating an efϐlux ratio for the
bi-directional transport was not possible. However, the binding did not affect basolateral
to apical transportwhichwas reduced solely due to P-gp inhibition. Testing in theMDCK II
model also allowed calculation of net efϐlux and determination of dose response curves for
P-gp modulation by Soluplus R.
Since calculation of EC50 values was dependent on the used system and on the used sub-
strate, the effect of Soluplus R on a speciϐic substrate can only roughly be predicted. Thus,
a possible interaction should be assessed in the development of formulations of P-gp sub-
strates with this excipient.
Themechanism of inhibition of P-glycoprotein by Soluplus R remains unclear. Among oth-
ers, membrane ϐluidization, ATPase inhibition or down regulation of the MDR1 gene are
possible causes for P-gp inhibition by excipients and might be addressed in further inves-
tigations.
No signiϐiant effect on the protease trypsin could be determined. However, investigations
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on a possible peptidase inhibition may be expanded to -chymotrypsin or carboxypepti-
dases in further studies.
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6. Optimization of Soluplus R formulations
- Drug binding to Soluplus R and its
effect on in vitro performance of
Soluplus R
Parts of this chapter are planned for a future publication as journal article.
Abstract
The applicability of Caco-2monolayers as predictive tool for the in vivo absorption of Solu-
plus R formulated drugs was previously demonstrated (see Chapter 4). Therefore, Caco-2
transport experimentswere used for an optimization of Soluplus R/drug formulations. As
shown by dialysis experiments, drugs may be entrapped in Soluplus R micelles and hence
hindered in their transport across the cells. For further investigation of this phenomenon,
the inϐluence of changes in the Soluplus R/drug ratio on the transport across Caco-2 cells
was tested. Besides binding betweendrug and excipient, also the solubilization capacity of
Soluplus R plays an important role for this optimization. By increasing the drug concentra-
tion in an extrudate, the drug will appear not only in amorphous state but also crystalline.
Also the concentration of Soluplus R after dissolution is reduced in such high drug loaded
extrudates which may lead to a diminished solubilization of the drug.
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Caco-2 transport experiments showed an optimal excipient/drug ratio for the drug ϐlux of
the tested drugs danazol, itraconazole and fenoϐibrate. The more or less sharp optimum
is dependent on the respective drug and was found between ratios of 0.01–0.5 [n/n]. For
higher ratios the transport was decreased, probably due to binding of drug and excipient.
The decreased transport for ratios below the optimum may be explained by two factors:
a) slower dissolution of the partially crystalline extrudates and b) reduced solubilization
due to the reduced Soluplus R concentration.
6.1. Introduction
Poorly soluble APIs are today one of the most important challenges for pharmaceutical
technology. Especially in solid oral dosage forms, their characteristically poor dissolu-
tion rate in the gastro-intestinal ϐluids hinders these drugs from absorption through the
intestinal mucosa. According to the equation of Noyes-Whitney (Equation 3.1), a lower
particle size results in a higher dissolution rate. This leads to the development of formu-
lations with reduced particle sizes, such as micronized powders or nanoparticles. Also
novel formulation techniques as spray drying, cogrinding or the use of supercritical ϐluids
for micronization were used. The maximal reduction of particle size is reached if the drug
is molecularly dispersed. Molecular dispersion of a drug may be reached by embedding
the API in small polymer particles or by adsorption to small (porous) particles. The main
drawback of this formulation approaches is their typically low yield. Accordingly these
methods are challenging to scale-up and therefore also time and cost intense.
Another approach to molecularly dispersed solid forms is the production of solid solu-
tions. In a solid solution, the API is molecularly dispersed and entrapped in a polymer
matrix. This design leads to increased dissolution rates, as the particle size is reduced to
theminimum. Solid solutions are stable upon crystallization if the drug shows a sufϐicient
solubility in the polymer (see Chapter 3.3). If the concentration of the drug in a solid solu-
tion is exceeded, a glass suspension is formed (see Table 3.5). While a biphasic amorphous
system still may show superior dissolution rates, a crystalline drug in a solid dispersion is
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similar to a physical mixture of crystalline drug and the respective polymer. Such a bipha-
sic amorphous solid solution is kinetically unstable and is vulnerable to crystallization by
storage, milling or other process steps.
In the present study, the absorption behavior of Soluplus R formulations was investigated
by use of the Caco-2 cell culture model. Transport experiments across Caco-2 monolayers
are awidely accepted tool to estimate intestinal drug absorption (see also Chapter 3.5). As
described above, the Caco-2 model is applicable to formulations with the novel excipient
Soluplus R and allows good predictions of their in vivo absorption behavior (see Chapter
4).
Previously, a many fold increase of drug absorption in vivo and in vitrowas proven if these
drugs were applied as solid solution with Soluplus R. Furthermore, it was shown that
these drugs bind to the excipient which may lead to a reduced absorption. Therefore, a
decrease or increase of the Soluplus R concentration in a solid solution may lead to in-
creased or decreased binding and consequently to an altered drug absorption.
In this study the effect of changes in the ratio between drug and excipient was inves-
tigated. Starting from solid solutions containing 15% (danazol/itraconazole) or 20%
(fenoϐibrate), which were used for animal experiments, the drug part was adjusted to val-
ues between 0.5–70%. For lower drug parts (higher Soluplus R/drug ratio) this was real-
ized by addition of Soluplus R to the respective solid solution. For higher drug parts (lower
ratio) hot melt extrudates were produced. As described above, the molecular dispersity
of the API is not guaranteed in such high loaded extrudates.
The interplay between binding, crystallization and solubilization leads to an optimal Solu-
plus R/drug ratio for each API. It was shown that increased ratios cause decreased drug
ϐluxes as result of binding. On the other hand, ratios below the optimum lead to reduced
drug ϐluxes upon dissolution problems. Although these results were not yet validated in
animal experiments, our data underscores the value of the Caco-2 model as versatile tool.
It is not only useful for simple permeability testing, but also for optimization ofmore com-
plex formulations, such as solid dispersions. So, if these results once can be conϐirmed in
vivo, the potency of this model also for optimization purposes will be further supported.
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%API [w/w] Temperature [C] Powder feed rate [kg/h] rpm
Danazol 5, 15, 25, 35, 45, 60 140 0.9 200
Fenoϐibrate 10, 20, 30, 40, 60 95 0.7 200
Itraconazole 15, 30, 45, 60, 70 150 1 200
Table 6.1.: Melt extrusion parameters for production of the used solid dispersions
6.2. Materials and Methods
6.2.1. Chemicals
Soluplus R was obtained from BASF SE (Ludwigshafen, Germany). Itraconazole and dana-
zol were purchased from Selectchemie AG (Zurich, Switzerland). Non-essential amino
acids (NEAA) and Dulbecco’s modiϐied Eagle’s medium (DMEM) were provided by PAA
Laboratories GmbH (Pasching, Austria). PAN-Biotech GmbH (Aidenbach, Germany) deliv-
ered fetal bovine serum. Vitamin E TPGS was from Eastman Chemical Company (Kings-
port, TN, USA). Transwell permeable ϐilters (type 3460, 0.4 µm pore size, polycarbonate)
were supplied by Corning Inc. Life Science (Lowell, MA, USA). Fenoϐibrate and all other
chemicals were from Sigma-Aldrich (St. Louis, MO, USA).
6.2.2. Extrudates
Solid dispersions of Soluplus R and the drugs danazol, fenoϐibrate and itraconazole were
produced by hot melt extrusion at BASF SE. All extrudates were manufactured by a Ther-
moFisher Polylab twin-screw extruder (ThermoFisher Scientiϐic Inc., Watham, MA , USA).
An overview of the used extrudates and their extrusion parameters is given in Table 6.1.
All extrudates were milled by an impact mill (Clatronic KSW 3306, coffee grinder) before
use.
6.2.3. Caco-2 cell culture
Caco-2 cells (of clone C2BBe1) were purchased from American Type Culture Collection
(Manassas, CA, USA). DMEM, supplied by 10% FBS and 1%NEAAwas used as cell culture
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medium. Mediumwas replaced every 2–3 days. Cellswere subcultivated at a conϐluency of
90% once a week. For transport experiments cells of passages 63–80 were used. There-
fore, 60,000 cells were seeded on Transwell permeable membrane inserts. After 21–23
days of growth and differentiation cells were used for transport experiments. Caco-2 cells
were grown under conditions of 37 C, 80% relative humidity and an atmosphere of 5%
CO2. As qualiϐication criteria for transport studies experiments served the transepithelial
electrical resistance (TEER): Only monolayers providing TEER values above 500 Ohm x
cm2 were used for transport experiments.
6.2.4. Caco-2 transport experiments
Krebs Ringer buffer (KRB)was used as transportmedium (TM). This buffer includes 114.2
mMNaCl, 3.0mMKCl, 4.0mMd-glucose, 1.4mMCaCl2, 2.6mMMgCl2 and10.0mMHEPES.
By addition of NaOH the pH was equilibrated to a value of 7.4. As the tested drugs are not
sufϐiciently soluble in TM, 0.2%VitaminETPGS (danazol, fenoϐibrate) or 1%HPCD (itra-
conazole) was added to the receiver compartment to maintain sink conditions.
The respective formulations (solid solutions & physical mixtures) of the drugs were dis-
solved in KRB for one hour before application to the cells. Therefore, the formulations
were weighed in for a ϐinal drug concentration of 0.5mg/ml (danazol/itraconazole) or
1mg/ml (fenoϐibrate), representing a single oral dose dispersed in 200ml ingested liquid.
To simulate the dissolution in the GI, these dispersions were stirred on a magnetic stirrer.
The used formulations for each drug are summarized in Table 6.2.
ID
mass ratio
(SP/drug)
molar ratio
(SP/drug)
molar ratio
(drug/SP)
Final SP
conc. [%]
Remarks Picture
Danazol
0D 0 0 n.d. 0 no Soluplus R
PMd1 0.10 2.8610 4 3496.7 0.005
PMd2 0.20 5.7210 4 1748.36 0.01
PMd3 1.00 2.8610 3 349.67 0.05
PMd4 2.00 5.7210 3 174.84 0.1
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ID
mass ratio
(SP/drug)
molar ratio
(SP/drug)
molar ratio
(drug/SP)
Final SP
conc. [%]
Remarks Picture
PMd5 5.67 0.016 62.44 0.28
PMd6 20 0.057 17.48 1
PMd7 40 0.114 8.74 2
PMd8 60 0.172 5.83 3
PMd9 100 0.286 3.5 5
PMd10 200 0.572 1.75 10
SDd1 0.67 1.9110 3 524.51 0.033
60% danazol
extrudate
SDd2 1.22 3.5010 3 286.09 0.061
45% danazol
extrudate
SDd3 1.86 5.3110 3 188.29 0.093
35% danazol
extrudate
SDd4 3.00 8.5810 3 116.56 0.15
25% danazol
extrudate
SDd5* 5.67 0.016 62.44 0.28
15% danazol
extrudate
SDd6 10 0.029 34.97 0.5 spiked
SDd7 19 0.054 18.40 0.95
5% danazol
extrudate
SDd8 20 0.057 17.48 1 spiked
SDd9 40 0.114 8.74 2 spiked
SDd10 60 0.172 5.83 3 spiked
SDd11 100 0.286 3.50 5 spiked
SDd12 200 0.572 1.75 10 spiked
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ID
mass ratio
(SP/drug)
molar ratio
(SP/drug)
molar ratio
(drug/SP)
Final SP
conc. [%]
Remarks Picture
Fenoϐibrate
0F 0 0 n.d. 0 no Soluplus R
PMf1 0.01 3.0610 5 32702 0.001
PMf2 0.1 3.0610 4 3270.2 0.01
PMf3 0.5 1.5310 3 654.1 0.05
PMf4 1.5 4.5910 3 218.0 0.15
PMf5 2.33 7.1410 3 140.15 0.233
PMf6 4 0.012 81.76 0.4
PMf7 10 0.031 32.70 1
PMf8 30 0.092 10.90 3
PMf9 50 0.153 6.54 5
PMf10 100 0.306 3.27 10
SDf1 0.67 2.0410 3 490.54 0.067
60% feno
extrudate
SDf2 1.5 4.5910 3 218.0 0.15
40% feno
extrudate
SDf3 2.33 7.1410 3 140.15 0.233
30% feno
extrudate
SDf4* 4 0.012 81.76 0.4
20% feno
extrudate
SDf5 9 0.028 36.34 0.9
10% feno
extrudate
SDf6 10 0.031 32.70 1 spiked
SDf7 30 0.092 10.90 3 spiked
SDf8 50 0.153 6.54 5 spiked
SDf9 100 0.306 3.27 10 spiked
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ID
mass ratio
(SP/drug)
molar ratio
(SP/drug)
molar ratio
(drug/SP)
Final SP
conc. [%]
Remarks Picture
Itraconazole
SDi1 0.43 2.5610 3 390.19 0.021
70% itra
extrudate
SDi2 0.67 3.9910 3 250.86 0.033
60% itra
extrudate
SDi3 1.22 7.3110 3 136.82 0.061
45% itra
extrudate
SDi4 3.33 0.020 50.16 0.167
30% itra
extrudate
SDi5* 5.67 0.034 29.86 0.28
15% itra
extrudate
SDi6 20 0.120 8.36 1 spiked
SDi7 40 0.239 4.18 2 spiked
SDi8 100 0.598 1.67 5 spiked
SDi9 200 1.196 0.84 10 spiked
Table 6.2.: Soluplus R(SP)/drug formulations used for Caco-2 transport experiments: PM indicates physical mixtures,
SD indicates solid dispersions; formulations labeled by “spiked” are mixtures of the respective solid solution
(marked by *) and additional Soluplus R .
For transport experiments Caco-2 monolayers were washed twice with TM, followed by
1.0 h pre-incubation time. On the apical side of the Transwell system 500 µl of the respec-
tive sample was applied, while the basolateral compartment was ϐilled with 1500 µl of the
respective acceptor medium (KRB + TPGS/HPCD). Transport from apical to basolateral
side was studied over 4 hours under cell culture conditions. During incubation cells were
agitated on an orbital shaker (100 ± 20 rpm) and samples of 200 µl volume were drawn
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from the basolateral compartment at 30, 60, 90, 120 and 180minutes. The removed sam-
ple volume was replaced by the same volume of fresh prewarmed TM (+ TPGS/HPCD).
For each well the drug ϐlux was calculated by the formula:
Flux =
dc
dt
 1
A
(6.1)
Hereby dc/dt indicates the slope of the linear permeation curve and A the surface of the
monolayer.
As control experiment for the inϐluence of drug binding to Soluplus R, transport exper-
iments using the low permeability marker ϐluorescein sodium were conducted. There-
fore, 10 µM solutions of ϐluorescein sodium in KRB, containing different amounts of Solu-
plus R, were prepared. Those solutions were applied on the apical side of the Transwell
system and transport across Caco-2 monolayers was studied over 4 hours (conditions as
above). Fluorescein sodiumwas detected ϐluorometric at awavelength of 480 nm/530nm
(emission/excitation) on a 96well plate reader type Tecan inϐinite 200 (Tecan Group Ltd,
Männedorf, Switzerland). For ϐluorescein sodium the apparent permeability (Papp) was
calculated by the formula:
Papp =
dc
dt
 1
c0
 1
A
(6.2)
Whereas dc/dt represents the slope of the permeation curve, c0 the initial donor concen-
tration and A the cell surface.
6.2.5. HPLC analysis
All samples were diluted by the same volume of either acetonitrile (fenoϐibrate, itracona-
zole) or methanol (danazol).
The mobile phase for analysis of danazol consisted of methanol:water:phosphate buffer
pH 6.8 [80:17:3 (v/v/v)]. Samples of 50 µl were injected on a reversed phase column [Li-
ChroCART 125-4 LiChrospher 100 RP18 (5 µM) by Merck KGaA (Darmstadt, Germany)].
UV/Vis absorptiometry was used for detection at a wavelength of 288 nm.
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A mixture of water (acidiϐied to pH 2.5 by phosphoric acid) and acetonitrile at a ratio of
70:30 (v/v) was used for quantiϐication of fenoϐibrate and its metabolite fenoϐibric acid.
Both compoundswerequantiϐied absorptiometric at awavelength of 286 nm. 50 µl of each
sample were injected on a reversed phase column (RP18 as above).
Itraconazolewas injected at a sample volumeof 80 µl on a reversedphase column (RP18as
above) and eluted by amixture of acetonitrile, water and phosphate buffer pH 6.8 [70:27:3
(v/v/v)]. Samples were analyzed by UV/Vis absorptiometry at a detection wavelength of
263 nm. Additional data on the used HPLC analytics can be found in Appendix C.
6.2.6. Equilibrium dialysis
Equilibrium dialysis was performed to conϐirm the binding of Soluplus R to ϐluorescein
sodium. Therefore, ϐluorescein/Soluplus R solutions (as for transport experiments) were
dialyzed for 4 hours at 37 C versus pure KRB.
Experiments were performed by a dialysis system consisting of two chambers with a vol-
ume of 2ml each. Chambers were separated by a cellulose membrane providing a mol-
ecular cutoff of 10 kDa (Harvard Apparatus, Holliston, MA, USA). Dialysis chambers were
rotated by aDIANORMapparatus (identical to DIALYZER byHarvard Apparatus, Holliston,
MA, USA).
Results are expressed as ratio between donor and acceptor (D/A ratio), indicating the
binding strength between exception and ϐluorescein.
6.2.7. Differential scanning calorimetry (DSC)
Differential scanning calorimetry was performed to distinguish between (partially) crys-
talline and amorphous solid dispersions. A sample of 3–7mg was weighed into a her-
metic aluminium container and analyzed at a heating rate of 10 C/min by a TA Instru-
ments Q100DSC (TA Instruments, New Castle, DE, USA). The heat ϐlow [Watts per gramm]
was measured and plotted versus the temperature. Changes in heat ϐlow are indicating
exothermic or endothermic processes.
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w/o Soluplus
B
Figure 6.1.: A: Fluorescein sodium transport across Caco-2monolayers (n=3; mean SD).
B: Equilibriumdialysis of Soluplus R/ϐluoresceinmixtures, donor/acceptor ra-
tios vs. Soluplus R concentration (n=5; mean SD)
6.3. Results
6.3.1. Fluorescein sodium (control)
Transport experiments with ϐluorescein sodium showed a concentration dependent de-
crease of Papp values by increasing Soluplus R concentration (Figure 6.1 A).While the con-
trol experiment (without Soluplus R) established a Papp of 7.8 x 10-7 cm/s, a strong de-
crease of the apparent permeability was detected by addition of the excipient. An addition
of 5% Soluplus R decreased the Papp more than 10-fold to a value of 6.0 x 10-8 cm/s. To
conϐirm the hypothesis that this decrease is due to binding of the substrate to Soluplus R,
equilibrium dialysis was performed.
As shown in Figure 6.1 B, Soluplus R was able to retain ϐluorescein sodium in the donor
compartment, expressed in donor/acceptor ratios > 1. By increasing Soluplus R concen-
tration, the binding strength increased. While for low concentrations almost an equilib-
rium was reached (D/A=1), the binding strength increased up to a donor/acceptor ratio
of 9.3 for a 5% Soluplus R solution.
A concentration dependent binding of Soluplus R to ϐluorescein sodium was proven by
equilibrium dialysis. Therefore, the decreased apparent permeability in Caco-2 transport
experiments is most probably due to this binding.
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PMd9
B
Figure 6.2.: Dependency of danazol ϐlux on Soluplus R/drug ratio (n=3–9; mean SD). A:
solid dispersions; B: physical mixtures. Labels refer to Table 6.2, page 72.
6.3.2. Danazol
Solid dispersions
The drug ϐlux of danazol across Caco-2 monolayers was dependent on the Soluplus R/
danazol ratio of the respective formulation. As demonstrated in Figure 6.2 A the high-
est ϐlux was established by the extrudate containing 25% danazol. While this formulation
showeda ϐluxof 26.27 ngmin-1 cm-2, the ϐluxdecreasedby increasingSoluplus R/drug
ratio to a value of 4.83 ng min-1  cm-2 for a mass ratio of 200. On the other hand, the
drug ϐlux decreased as well for decreasing Soluplus R/drug ratios. For the extrudate con-
taining 60% danazol the ϐlux was reduced to 15.79 ngmin-1  cm-2.
Differential scanning calorimetry of the used extrudates proved the existence of crystalline
drug in the extrudates containing 35%, 45% and 60% danazol by the presence of melt-
ing peaks in the respective DSC thermogramms (Figure 6.3). However, the melting peaks
were not as exposed as for the pure drug, indicating a coexistence of amorphous and crys-
talline parts in the extrudates. Also the exothermic disintegration peaks of both danazol
and Soluplus R [62] at temperatures above 250 C complicated a more exact analysis of
the DSC data. An estimation of the crystallinity of an extrudate can also be done by optical
investigation: while real solid solutions appear clear, partially crystalline extrudates are
turbid (Table 6.2).
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Figure 6.3.: DSC of the used danazol hot melt extrudates (Exotherm up). Melting peaks of
extrudates are shifted to lower temperatures, probably due to the formation
of polymorphs and/or eutectics.
Physical mixtures
As shown in previous experiments, the in vivo and in vitro absorption of physical mixtures
of crystalline danazol and Soluplus R is comparable to the absorption of the pure drug
(see Chapter 4.3.1). However, an effect of the excipient/drug ratio was also detectable for
the physical mixture (Figure 6.2 B). Especially for high Soluplus R/drug ratios a decreased
drug ϐlux was detected. While the formulation with a ratio of 5.67 (= 15% danazol) es-
tablished a ϐlux of 2.63 ngmin-1  cm-2, the ϐlux decreased to a value of 0.90 ngmin-1
 cm-2 for a ratio of 200. Contrarily, by decreasing ratio the ϐlux was slightly increased
compared to the pure drug (2.67 ngmin-1  cm-2). However, if the total Soluplus R con-
centration reached its CMC, the ϐluxwas obviously comparable to the ϐlux of the pure drug.
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Figure 6.4.: Dependency of fenoϐibrate ϐlux on Soluplus R/drug ratio (n=3–6; mean SD).
A: solid dispersions; B: physical mixtures. Labels refer to Table 6.2, page 72.
6.3.3. Fenoϐibrate
The prodrug fenoϐibrate is metabolized to its active form fenoϐibric acid during transport
across Caco-2 cells. Therefore, all results are related to this metabolite.
Solid dispersions
As for danazol, the drug ϐluxwas dependent on the ratio between excipient and fenoϐibrate
(Figure 6.4). The optimum is less exposed as for danazol and located at a ratio of 2.33 (Ta-
ble 6.2-SDf3), enabling a ϐlux of 102.83 ngmin-1  cm-2. For higher ratios the drug ϐlux
decreased to a value of 54.9 ngmin-1  cm-2 for a ratio of 100. Both tested formulations
below the optimum (Table 6.2-SDf1 & SDf2) showed lower ϐluxes with 98.65 ng  min-1
 cm-2 and 79.00 ng  min-1  cm-2, respectively. Compared to danazol, the optimum is
less exposed and a certain range for a high ϐlux could be determined for Soluplus R/drug
ratios between 1.5 and 9 (m/m).
The DSC thermogramms of the used extrudates offer clear melting peaks of crystalline
drug for the extrudates, containing 40% and 60% fenoϐibrate (Figure 6.5). Also for the
extrudatewith 30% fenoϐibrate, which established themaximal ϐlux, a certain crystallinity
can be assumed. However, the overlay between the Tg of Soluplus R ( C; Figure 6.6) and
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Figure 6.5.: DSC of the used fenoϐibrate hot melt extrudates (Exotherm up). Melting peaks
of extrudates are shifted to lower temperatures, probably due to the formation
of polymorphs and/or eutectics.
the melting peak of fenoϐibrate (m.p. 80.5 C) hinders an exact determination of the crys-
talline parts. For all extrudates, no melting peaks of the metabolite fenoϐibric acid (m.p.
179–183 C)was found. Optical examination of the extrudates conϐirmed the DSC data, as
the high loaded extrudates appeared turbid, the 30%extrudatemostly clear and the lower
loaded extrudates entirely clear (Table 6.2).
Physical mixtures
Previous in vitro and in vivo studies showed that Soluplus R enhances the absorption of
fenoϐibrate not only in a solid solution, but also in a physical mixture of drug and excipient
(Chapter 4.3.2).
Also for the physical mixture, the drug ϐlux was dependent on the Soluplus R/drug ratio.
Amaximal ϐlux was reached for a ratio of 0.5 (m/m)with 75.71 ngmin-1  cm-2. As well
as for the solid solution, the ϐlux decreased for both lower and higher ratios. Obviously,
the ϐlux was decreased to the same level as for the pure drug if the total Soluplus R con-
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Figure 6.6.: DSC thermogramm of Soluplus R (Exotherm up). Tg is slightly shifted to lower
temperature.
centration in the medium reached its CMC (Figure 6.4). Interestingly, the drug ϐluxes of
formulations PMf3 (75.71 ng  min-1  cm-2) and SDf1 (79.00 ng  min-1  cm-2) were
similar which indicates that fenoϐibrate is mostly present in the crystalline form in the
solid dispersion and therefore behaved similar to a physical mixture (Figure 6.7).
6.3.4. Itraconazole
For itraconazole, the absorption in vitro and in vivo for the physical mixture and for the
pure drug remained very low (Chapter 4.3.3). Therefore, no experiments using the physi-
cal mixture and the bulk drug were conducted in this study.
For solid dispersions with itraconazole a clear dependence of the drug ϐlux across Caco-2
monolayers on the Soluplus R/drug ratio was detected (Figure 6.8). A maximal ϐlux was
determined for a mass ratio of 20 (17.54 ng  min-1  cm-2). However, a broad range of
ratios can be considered as optimal: ratios between 3.33 and 40 lead to similar ϐlux values.
In contrast, by exceeding a ratio of 40, the ϐlux strongly decreased, down to a ϐlux of 6.39 ng
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w/o Soluplus
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SDf4*
Figure 6.7.: Comparison between solid dispersions and physical mixtures of Solu-
plus R/fenoϐibrate. Drug ϐluxes of themetabolite fenoϐibric acid (n=3–6; mean
 SD). Labels refer to Table 6.2, page 72.
SDi1
SDi2
SDi3
SDi4
SDi5* SDi6 SDi7
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SDi9
Figure 6.8.: Dependency of itraconazole ϐlux on Soluplus R/drug ratio (n=3–6; mean 
SD). Labels refer to Table 6.2, page 72.
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Figure 6.9.: DSC of the used itraconazole hot melt extrudates (Exotherm up). Melting
peaks of extrudates are shifted to lower temperatures and doubled, probably
due to the formation of polymorphs and/or eutectics.
min-1  cm-2 for a ratio of 200. Also for decreasing ratios a decreased itraconazole ϐlux
was detected. For the extrudate containing 70% itraconazole (Table 6.2-SDi1), the ϐlux is
reduced to a value of 8.54 ngmin-1  cm-2.
DSC data of the used solid dispersions demonstrated crystalline drug parts in extrudates
containing 45% itraconazole or more (Figure 6.9). This is in concordance with an optical
investigation of the extrudates. As those high loaded dispersions showed strong turbidity
compared to the extrudates with less than 45% drug. However, the strong transport of
the highest loaded extrudate (SDi1), compared to the pure drug and the physical mixture,
indicates the presence of fast dissolving amorphous parts. Double melting peaks in the
DSC thermogramms were most probably due to the formation of different polymorphs of
the drug through hot melt extrusion.
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6.4. Discussion
Transport experiments across Caco-2 monolayers demonstrated an optimal Soluplus R/
drug ratio for the absorption of danazol, fenoϐibrate and itraconazole solid dispersions
(Figure 6.11 A). Also for physical mixtures of danazol and fenoϐibrate with Soluplus R an
optimal ratio of drug and excipient could be determined.
The decreased drug ϐlux of Soluplus R/drug ratios below the optimum may be explained
by the appearance of crystalline drug in these extrudates. As shown by DSC and/or opti-
cal investigation, the existence of crystalline drug leads to reduced drug ϐlux across the cell
monolayer. This behavior canmost probably be explained by the slow dissolution of these
solid dispersions. Real solid solutions (see Table 3.5) show a rapid dissolution, due to the
molecularly dispersed drug and therefore minimal particle size of the drug. In contrast,
for solid dispersions (cf. Table 3.5) the drug is not molecularly dispersed and hence not
present in the optimal particle size. Especially if the drug is present in its crystalline form,
the dissolution is hindered as the lattice energy has to been overcome for a successful
solubilization. Although the solubility enhancer Soluplus R is present, the slower disso-
lution of crystalline drugs leads to reduced transport, as the time scale for solubilization
of the drug is limited by the duration of the experiment which tries to mimic the in vivo
time window available for drug dissolution and absorption in the gut and small intestine.
Besides slower dissolution of these high loaded extrudates, the lower Soluplus R concen-
tration available for solubilization decreases the free and dissolved drug amount thus the
drug ϐlux: In this series of experiments the drug concentration was ϐixed to 0.5mg/ml
(danazol & itraconazole) or 1.0mg/ml (fenoϐibrate), the ϐinal Soluplus R concentration in
the transport medium is consequently reduced for low Soluplus R/drug ratios. As shown
in Table 6.2, the ϐinal Soluplus R concentration is reduced to 0.021–0.33% for the lowest
Soluplus R/drug ratios. According to equation 3.2, the solubility of the respective drug is
reduced at low surfactant concentrations. This also results in a decreased transport for
low Soluplus R/drug ratios in physical mixtures of drug and excipient. However, as the
curves for physical mixture and solid dispersion offer differing excipient/drug ratios for
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the maximal ϐlux, it can be assumed that both, the slower dissolution due to crystalline
drug and decreased solubilization due to low Soluplus R concentrations, play a role for
the reduced ϐlux. The predominance of the high loaded extrudates versus the physical
mixtures is most probably due to the coexistence of solubilized molecularly dispersed,
amorphous not solubilized and crystalline drug in the used extrudates.
For Soluplus R/drug ratios above the optimum, the drug ϐlux decreased for all three tested
drugs. As shown by Caco-2 transport and equilibrium dialysis experiments using ϐluores-
cein sodium as dye, Soluplus R shows a concentration dependent binding to this marker
substrate. Also for the used drugs a certain binding between drug and excipient could be
determined by equilibrium dialysis (see Chapter 4.3.4). Therefore ,the decreased ϐlux is
most probably due to this binding behavior. The total Soluplus R concentration seems not
toplay a role in this case, as formulationswithdifferent total Soluplus R (anddrug) concen-
trations, but with the same drug/excipient ratios showed a similar drug ϐlux: For example,
a 7-fold higher initial weight in sample SDd5* leads to a ϐlux of 20.87  0.93 ng  min-1
 cm-2 (SDd5*: 21.48  1.67 ng  min-1  cm-2). The observed binding between drug
and excipient is likely dependent on the lipophilicity of the respective drug: equilibrium
dialysis of different drugs and ϐluorescence dyes showed a logP dependent increase of the
binding, quantϐied by increasing donor/acceptor ratios (Figure 6.10). Hereby, fenoϐibrate
and its metabolite fenoϐibric acid seem to be outliers. This is also in concordance with the
differing behavior of fenoϐibrate in vivo and in vitro (see Chapter 4.3.2). The slope of the
terminal decrease is also dependent on the drug and coincides with the order of the bind-
ing strength: itraconazole >danazol > fenoϐibrate (Figure6.11B&Figure 6.10). Decreased
transport by a surplus of a solubilizing excipient is not a new phenomenon. For instance it
was shown for formulations of HPCD with ϐlutamide, that a stable excipient/drug com-
plex may hinder the transport across Caco-2 cells [122]. However, the advantage of an en-
hanced aqueous solubility overcompensates the reduced drug ϐlux, as most of the tested
formulations showed a signiϐicantly higher absorption than the pure crystalline drug.
The excipient/drug ratio for establishing a maximal ϐlux is dependent on the used drug
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Figure 6.10.: D/A ratios of equilibrium dialysis (at a Soluplus R concentration of 0.5%)
correlates to logP values of the respective drug (Logarithmic ϐit R2=0.9819).
Except for the marked outliers fenoϐibrate and fenoϐibric acid.
A B
Figure 6.11.: A: Excipient/drug ratio versus drug ϐlux. Y-axis is normalized to the respec-
tive “Standard formulation” (marked by * in Table 6.2). B: Logarithmic ϐit of
the terminal decrease added to Graph A. R2=0.9495, 0.9510 and 0.9795 for
itraconazole, fenoϐibrate and danazol, respectively.
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(Figure 6.11 A). These maxima are composed of solubilization and binding of the drug
with Soluplus R. The highest ϐlux is established if just enough Soluplus R is apparent for
a successful formation of a stable solid solution. If a surplus of the excipient is present,
the ϐlux decreases as result of binding. Therefore, the composition of the Soluplus R/drug
complex is of further interest for a better understanding of this behavior.
Since the respective drug is bond by the formed Soluplus R micelles, the micelle size was
studied by dynamic light scattering (see Appendix A). While no or only low difference be-
tween drug-loaded and unloaded micelles could be determined, the total Soluplus R con-
centration affects the micelle size. Especially at high Soluplus R concentrations, which
were also present in this study, the micelles seem to be differentially shaped or aggregat-
ing. Also the possible formation of rod-like or layered structures may change the release
of API from the micelles. Another factor that may affect the stability of the micelle/drug
complex is the pH, the presence of salts, and/or additional micelles. DLS showed no effect
of the pH on micelle size, but the osmolarity of the used solvent lead to changes in micelle
size.
Especially for a transfer to the in vivo situation this might play a role. The intestinal ϐluids
are complexly composed andmicelles formed by bile salts and phospholipids are present.
Therefore, the formation of mixed micelles with Soluplus R or a changeover of solubilized
drug from Soluplus R micelles to natural micellesmight affect the drug absorption.
While for danazol and fenoϐibrate the optimal ratio is located at the respective ratio of the
highest loaded extrudate without crystalline drug (as determined by DSC and optical in-
vestigation). The optimum for itraconazole is shifted to higher ratios. A possible reason
for this shift is an interaction with the efϐlux transporter P-gp. As itraconazole is substrate
and inhibitor of this protein and Soluplus R is also suspected to inhibit P-gp (Chapter 5),
P-gp inhibition might compensate the reduced absorption provided by the formation of a
stable complex.
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6.5. Conclusion and Outlook
For solid dispersions of Soluplus Rwith danazol, fenoϐibrate and itraconazole an optimum
for drug transport across Caco-2 cells was found. This optimum is the result of three (itra-
conazole: four) effects:
1. In high loaded extrudates drug crystals are present which do not dissolve rapidly in
the used timescale
2. The ϐinal Soluplus R concentration must be high enough for a successful solubiliza-
tion of the drug
3. The formation of stable drug/excipient complexes leads to a reduced absorption for
high Soluplus R/drug ratios
4. For itraconazole an interference with inhibition of active efϐlux by P-gp might inter-
fere with the optimum formed by 1.–3.
Based on the results of this Caco-2 experiments a rule of thumb for the formulation of
poorly soluble drugs with Soluplus R may be formulated: “Use only as much Soluplus R as
needed for a stable amorphous extrudate”. The stability is hereby expanded on the whole
manufacturing process, including possible steps of milling, pelletizing or compaction of
the extrudates.
The exact structure and mechanism of the stable complexes of drug and excipient is not
fully understood and might be an aim of further investigations, using techniques as mol-
ecular modeling or analytical ultracentrifugation. First results from analytical ultracen-
trifugation with itraconazole loaded Soluplus R proved the existence of compact micellar
structures, containing the drug (see Appendix A for details).
Also the behavior of Soluplus R micelles in vivomight be of interest for further studies. As
described above, the composition of the intestinal ϐluids may affect the observed binding
effects. However, a conϐirmation of the results from Caco-2 monolayers by animal studies
would be an excellent validation for the power of this tool as surrogate for intestinal drug
absorption.
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7. Summary and Outlook
Many new active pharmaceutical ingredients offer a poor oral bioavailability as conse-
quence of their poor aqueous solubility. One approach to overcome this solubility hurdle
is the use of hot melt extrusion to produce rapidly dissolving solid solutions. However,
a supersaturation formed by the dissolution of such an extrudate is not stable unless a
solubilizing agent stabilizes this solution. The novel polymer Soluplus R was speciϐically
designed to combine these two properties in one molecule: solubilization and the feasi-
bility to form solid solutions. The efϐicacy of such an excipient might be tested in classical
dissolution tests, but these tests can only give a rough estimate of the in vivo situation.
Hence, animal studies are still considered as the gold standard for testing the efϐicacy of
novel formulation approaches for poorly soluble drugs.
The Caco-2 cell culture model is widely accepted for the estimation of intestinal drug per-
meability and also as alternative for animal experiments. The aim of replacing and reduc-
ing animal studies by such in vitromodels as proposed by the so-called 3R concept has not
only ethical aspects, but also economic reasons. The work presented in this thesis proved
the applicability of the Caco-2 model for more complex drug delivery systems, such as
hot melt extrudates. The Caco-2 model was also used for an optimization of Soluplus R
solid solutions with regards to drug excipient ratios. Additionally, the effect of the novel
polymer Soluplus R on P-glycoprotein and trypsin as possible targets of drug-excipient in-
teractions was studied.
In the ϐirst part of this thesis, formulations of Soluplus R with the poorly soluble drugs
danazol, fenoϐibrate and itraconazolewere tested for their transport behavior across Caco-
2 cells. Data from these in vitro permeation experiments were correlated to in vivo data
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from previously performed animal studies. As solid drug formulations cannot be applied
directly on the cell surface, a dissolution step has to be included beforehand. While in
vivo the dissolution of the solid formmostly occurs throughout the gastric passage, in our
studies the formulationswere dissolved outside the cell culture systembefore application.
Our studies showed an excellent correlation between the drug ϐlux across Caco-2 mono-
layers and the AUC of animal plasma curves for all three drugs. Especially the absorption
enhancing effect of the solid solutions could exactly be modeled. Furthermore, we were
able to conϐirm the efϐicacy of a physicalmixture of fenoϐibrate and Soluplus R. Fenoϐibrate
was the only tested drug compound for which the physical mixture demonstrated a supe-
rior bioavailability compared to the pure drug. This singularity could be conϐirmed in the
Caco-2 model, further proving the value of the in vitro model as surrogate for intestinal
drug absorption of Soluplus R formulations.
As secondpart of thiswork the effect of Soluplus R on the efϐlux transporter P-glycoprotein
was studied. This transporter protein may reduce the intestinal absorption of certain
drugs and is also the target of possible drug/excipient interactions. As many solubilizers
were shown to inhibit P-glycoprotein, the novel solubilizer Soluplus Rwas also tested for a
possible interaction. Cell culture assays using Caco-2 andMDCK-II cells proved the poten-
tial of Soluplus R to inhibit the efϐlux transporter. The effective concentration of Soluplus R
was comparably high and in the range of polyethylene glycols which are commonly clas-
siϐied as unproblematic excipients. Therefore, the in vivo relevancy of this inhibition may
be called into question.
The Caco-2 model was also used for an optimization of Soluplus R formulations. Since it
was shown by dialysis experiments that Soluplus R has the potential to retain drugs in a
complex by binding, the effect of increased or decreased Soluplus R (per drug) concentra-
tions on the transport of danazol, fenoϐibrate and itraconazole was tested. Our transport
studies showed that this binding leads to a strongly decreased permeation of all tested
drugs by increasing Soluplus R/drug ratios. Therefore, the popular lore more is better is
certainly not applicable to formulations containing Soluplus R. However, Soluplus R/drug
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ratio can only be reduced to a certain point: If the excipient/drug ratio gets too low, a sta-
ble solid solution cannot be formed. In this case, the amount of Soluplus R in the respective
extrudate is not sufϐicient to solubilize thedrug, hence the extrudate is partially crystalline.
Accordingly, the drug ϐlux decreases as result of the reduced dissolution of such a partially
crystalline formulation. For all tested drugs amore or less sharply expressed optimum for
the drug ϐlux across Caco-2 cells was found. This optimum seems to be the result of inter-
play between the effects of drug dissolution, solubilization and binding between drug and
excipient.
In all three parts of this work an unspeciϐic binding between Soluplus R and the respective
drug or P-gp substrate occurred and somehow affected the experimental outcome. There-
fore, a deeper investigation into this behavior should be considered. Dialysis experiments
showed that the strength of this binding is dependent on the compound and also corre-
lates mostly to the respective drug logP. Once again the outlier fenoϐibrate is remarkable
as the substance also showed some singularities in vivo and in Caco-2 transport. As Solu-
plus R gathers its solubilizing properties from the formation of micelles, these micelles
were further investigated by DLS measurements. While the micelle size was sensitive to
temperature changes, the enclosed drug molecules seemed not to affect the micellar size.
A certain effect of the used medium and its osmolarity on the micellar structures could be
determined.
This dependency on the used media leads to the question how these micelles behave in in
vivo liquids. If the micellar structure changes by alterations of the media, a different bind-
ing behavior between drug and excipient may be assumed. Accordingly, the use of more
biorelevant transport media might be considered in further studies. Fasted or fed state
simulated intestinal ϐluid (FaSSIF/FeSSIF) are more complex biosimilar media for disso-
lution tests, providing mixed micelles of bile salts and phospholipids [158]. Due to their
high osmolarity these media cannot be directly used in cell culture, but adaptions from
this ϐluids were developed for application on cells [159, 160, 161].
Another point, which may inϐluence the behavior of Soluplus R formulations in vivo, is the
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difference in the dissolution process compared to the Caco-2 model. While in our exper-
iments the dissolution step was performed by simple and delimited stirring in transport
buffer, the real situation is even more complex. In vivo the pH may change during the dis-
solution as it gradually increases during GI passage. One approach to simulate this effect
is the use of an acid dissolution medium to simulate the gastric passage and dissolution
which is subsequently equilibrated to a cell-compatible pH [106]. Also the dissolution in
vivo is not limited to a certain time window as in our experiments and absorption and
dissolution occur at the same time. To simulate this behavior the use of a combined disso-
lution/permeation systemmight be useful. Hereby a ϐlow-through dissolution cell is com-
bined with a permeation model such as Caco-2 cells [97, 162]. Such a system may lead to
even better correlations to the in vivo behavior and may further elucidate the mechanism
of bioavailability enhancement by Soluplus R. However, also our more simple approach
to simulate the dissolution step leads to excellent correlations with the in vivo behavior
of the tested formulations. Therefore, those more complex and hence more error-prone
systems might be considered as unnecessary. According to the principle of Occam’s razor
the simple method is to be favored over too complex systems.
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8. Zusammenfassung und Ausblick
Viele neue Arzneistoffe sind aufgrund ihrer schlechten Wasserlöslichkeit nur in gerin-
gemMaße oral bioverfügbar. Ein Forschungsansatz zur Überwindung dieser Hürde ist das
Schmelzextrusionsverfahren zur Herstellung schnellauϐlösender fester Lösungen. Durch
die Auϐlösung eines derartigen Extrudats entsteht eine Übersättigung, welche ohne Zusatz
eines Löslichkeitsverbesserers nicht stabil ist. Der neue polymere Hilfsstoff Soluplus R
wurde entwickelt, umdiese zwei Funktionen in einemMolekül zu vereinigen: Löslichkeits-
verbesserung sowie die Nutzbarkeit zur Herstellung fester Lösungen. DieWirksamkeit ei-
nes solchen Hilfsstoffes kannmit klassischen Dissolutionstests geprüft werden, allerdings
können diese Experimente nur eine vage Vorhersage für die in vivo Situation geben. Daher
gelten Tierversuche immer noch als Goldstandard zur Wirksamkeitsbestimmung neuer
Formulierungen für schwerlösliche Arzneistoffe.
Das Caco-2 Zellkulturmodel ist zum Einen ein weitverbreitetes und akzeptiertes Modell
zur Abschätzung der Arzneistoffaufnahme über die Darmwand und zum Anderen auch
eine akzeptierte Tierversuchsersatzmethode. Das Ziel durch derartigeModelle Tierversu-
che zu reduzieren, zu verfeinern und zu ersetzen (reduce, reϐine, replace = 3R-Konzept)
hat nicht nur ethische Gründe, sondern ist auch durch ökonomische Aspekte zu begrün-
den. Die in dieser Dissertation vorgestellte Arbeit konnte die Nutzbarkeit des Caco-2 Mo-
dells auch für komplexe Formulierungen wie Schmelzextrudate aufzeigen. Des weiteren
wurde das Caco-2 Modell genutzt, um feste Lösungen von Arzneistoffen mit Soluplus R zu
optimieren. Zusätzlich wurde der Effekt von Soluplus R auf P-glykoprotein und Trypsin
untersucht, welches mögliche Wirkstätten von Arzneistoff-Hilfsstoff-Interaktionen sind.
Im ersten Teil dieser Arbeit wurde das Transportverhalten der schwerlöslichen Arznei-
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stoffe Danazol, Fenoϐibrat und Itraconazol, in Formulierungenmit Soluplus R, über Caco-2
Zellen untersucht. Die Daten aus dieser in vitro Untersuchung wurden mit in vivo Daten
von zuvor durchgeführten Tierversuchen verglichen. Da feste Arzneistoffformulierungen
nicht direkt auf die Zellen appliziert werden können, muss zuvor eine Auϐlösung stattϐin-
den. Während in vivo die Auϐlösung des Arzneistoffs hauptsächlich während der Magen-
passage stattϐindet, so wurde in unseren Experimenten die Dissolution der Formulierun-
gen außerhalb des Zellkultursystems vorgenommen. Eine sehr gute Korrelation zwischen
dem Arzneistoffϐlux über Caco-2 Zellen und der AUC der Plasmakurven aus dem Tier-
versuch konnte für die drei getesteten Arzneistoffe gefunden werden. Insbesondere die
Absorptionsverbesserung durch die festen Lösungen konnte sehr gut vorhergesagt wer-
den. Zusätzlich wurde die Effektivität einer physikalischen Mischung aus Fenoϐibrat und
Soluplus R im Zellmodell bestätigt. Ausschließlich für Fenoϐibratwar die physikalischeMi-
schung der Reinsubstanz hinsichtlich der Bioverfügbarkeit überlegen. Diese Besonderheit
konnte im Caco-2-Modell bestätigt werden, was einen weiteren Beweis für die Mächtig-
keit dieses Testsystems als Modell für die intestinale Arzneistoffaufnahme aus Soluplus R-
Formulierungen darstellt.
Im zweiten Teil dieser Arbeit wurde dieWirkung von Soluplus R auf den Efϐluxtransporter
P-Glykoprotein untersucht. Dieses Transporterprotein ist in der Lage die intestinale Auf-
nahme diverser Arzneistoffe zu verringern. Außerdem ist P-Glykoprotein eine Zielstruk-
tur möglicher Arzneistoff/Hilfsstoff-Interaktionen. Da bereits für einige Löslichkeitsver-
besserer eine P-gp-Inhibition bewiesen werden konnte, wurde auch der neue Solubilizer
Soluplus R auf eine mögliche Interaktion mit diesem Transporter untersucht. In Zellkul-
turversuchen mit Caco-2 und MDCK-II Zellen konnte gezeigt werden, dass Soluplus R den
P-gp vermittelten Efϐlux hemmen kann. Die wirksame Konzentration von Soluplus R war
allerdings vergleichsweise hoch und beϐindet sich in etwa auf dem Niveau der Polyethy-
lenglykole, welche üblicherweise als unproblematisch hinsichtlich P-gp-Hemmung ange-
sehen werden. Aus diesem Grunde darf die Relevanz dieses Inhibitionsverhaltens für die
in-vivo-Situation in Frage gestellt werden.
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Im dritten Teil dieser Arbeit wurde das Caco-2 Modell zur Optimisierung von Soluplus R-
Formulierungen eingesetzt. Durch Gleichgewichtsdialyse wurde gezeigt, dass Soluplus R
Arzneistoffe in einem Komplex binden kann und dadurch vom epithelialen Transport zu-
rückhalten könnte. Daher wurde die Auswirkung einer erhöhten bzw. verringerten Solu-
plus R-Konzentration (pro Arzneistoff) auf den Transport über Caco-2 Zellen untersucht.
In Transportversuchen konnte gezeigt werden, dass diese Bindung mit steigendem Solu-
plus R/Arzneistoff-Verhältnis zu einer stark verringerten Permeation führt. Aus diesem
Grund ist die sprichwörtliche Empfehlung viel hilft viel nicht auf Arzneistoffformulierun-
gen mit Soluplus R anzuwenden. Die Menge an Soluplus R pro Arzneistoff kann allerdings
auch nur bis zu einem bestimmten Punkt reduziert werden: Wird das Hilfsstoff/ Arznei-
stoff-Verhältnis zu klein, so kann keine stabile feste Lösung gebildet werden. In diesem
Falle reicht die Soluplus R-Menge im Extrudat nicht aus, um eine ausreichende Löslichkeit
des Arzneistoffes zu gewährleisten, daher ist das jeweilige Extrudat zumindest teilweise
kristallin. Wegen der verringerten Dissolutionsrate einer solch teilkristallinen Formulie-
rung verringert sich derArzneistoffϐlux dementsprechend. Für alle drei Arzneistoffe konn-
te ein mehr oder weniger scharf ausgeprägtes Optimum für den Transport über Caco-2
Zellen gefundenwerden. Dieses Optimum ergibt sich aus dem Zusammenspiel der Effekte
Dissolutionsrate, Solubilisierung und Bindung zwischen Arzneistoff und Hilfsstoff.
In sämtlichen Teilen dieser Arbeit trat eine unspeziϐische Bindung zwischen Soluplus R
und dem jeweiligen Arzneistoff bzw. P-gp-Substrat auf und hatte auch Auswirkungen auf
das experimentelle Ergebnis. Aus diesem Grunde sollte eine weitere Untersuchung dieses
Verhaltens inBetracht gezogenwerden.Mittels Gleichgewichtsdialyse konnte gezeigtwer-
den, dass die Bindungsstärke substanzabhängig ist und weitestgehend mit dem logP der
jeweiligen Substanz korreliert. Beachtenswert ist hierbei wiederum der Ausreißer Feno-
ϐibrat, welcher auch im Tierversuch und in den Caco-2-Transportversuchen ein abwei-
chendes Verhalten zeigte. Da Soluplus R die Arzneistoffe durchMizellbildung solubilisiert,
wurden diese Mizellen mittels dynamischer Lichtstreuung weiter charakterisiert. Die Mi-
zellgröße ist temperaturabhängig, die eingeschlossenen Arzneistoffmoleküle beeinϐluss-
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ten die Mizellgröße jedoch nicht. Ein Effekt des verwendeten Mediums und dessen Osmo-
larität auf die mizellaren Strukturen konnte gezeigt werden.
Diese Abhängigkeit vom verwendetenMediumwirft die Frage auf, wie sich diese Mizellen
in den realen Körperϐlüssigkeiten verhalten. Da eine Veränderung des Mediums zu verän-
dertenMizellgrößen führt, so kannauchein verändertesBindungsverhalten zwischenArz-
neistoff und Soluplus R vermutet werden. Dementsprechend sollte die Verwendung bio-
relevanterer Transportmedien für zukünftige Studien in Betracht gezogen werden. Die si-
mulierten Intestinalϐlüssigkeiten FaSSIF und FeSSIF (fasted/fed state simulated intestinal
fluid) sind komplexe Medien, welche den realen Verdauungssäften im Dissolutionsverhal-
ten ähneln. Unter anderem enthalten diese Medien Mischmizellen aus Gallensalzen und
Phospholipiden [158]. Aufgrund ihrer hohen Osmolarität können diese Medien nicht di-
rekt auf Zellen angewendet werden, allerdings können diese Medien zur Anwendung auf
Zellen angepasst werden [159, 160, 161].
Ein weiterer Punkt welcher das Verhalten von Soluplus R-Formulierungen in vivo beein-
ϐlussen kann sind die Unterschiede in der Dissolution im Vergleich zum Caco-2 Modell. In
unseremVersuchwurde die Auϐlösung der Arzneistoffe durch einfaches Rühren im Trans-
portmedium über einen begrenzten Zeitraum durchgeführt. Die reale Situation ist sehr
viel komplexer: Unter anderem verändert sich der pHwährend der Dissolution durch den
pH-Gradienten imGastrointestinaltrakt. EineMöglichkeit diesenEffekt zu simulierenwäre
die Verwendung eines sauren Dissolutionsmediums, um die Auϐlösung während der Ma-
genpassage zu simulieren. Anschließend kann der pH dieses Mediums auf ein zellkompa-
tibles Niveau angehobenwerden [106]. Auch die Dissolution ist in der Realität nicht auf ei-
nen bestimmten Zeitraum beschränkt wie in unseren Versuchen, vielmehr können Disso-
lution und Arzneistoffabsorption gleichzeitig stattϐinden. Um dies zu simulieren könnte in
zukünftigen Versuchen ein kombiniertes Dissolutions- und Permeationssystem eingesetzt
werden. Hierbei wird eine Durchϐlussdissolutionszellemit einemPermeationsmodell, wie
zum Beispiel Caco-2-Zellen kombiniert [97, 162]. Solch ein System könnte zu noch bes-
seren Korrelationen des in vivo Verhaltens führen und könnte den Mechanismus der Bio-
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verfügbarkeitsverbesserung durch Soluplus R nochweiter ergründen. Andererseits zeigte
auch unsere recht einfache Simulation der Arzneiformauϐlösung sehr gute Korrelationen
zur Absorption der jeweiligen Formulierungen imTierversuch. Daher könnten diese kom-
plexeren und damit einhergehend auch fehleranfälligeren System auch als nicht notwen-
dig angesehenwerden. Dem Prinzip von Ockhams Rasiermesser folgend, ist der einfachere
Ansatz stets den komplexeren Systemen zu bevorzugen.
Dernächste Schritt für eineValidierungdes verwendetenCaco-2Modells als Tierversuchs-
ersatzmethode für die Absorption von Soluplus R-Formulierungen wäre eine Bestätigung
der Daten aus demOptimierungsansatz im Tierversuch. Falls in vivo Studien die Ergebnis-
se aus dem Caco-2 Modell bestätigen werden, könnte dieses Modell routinemäßig zur Op-
timierung von Soluplus R-Formulierungen eingesetzt werden. Dadurch könnten die For-
mulierungen so optimiert werden, dass einemaximal Absorption erreicht wird, was letzt-
endlich zu einer verringerten Dosis und dadurch auch verringerten Nebenwirkungen füh-
ren könnte. Auch das höhere Ziel Tierversuche einzusparen könnte erreichtwerden, wenn
Caco-2 Zellen routinemäßig zur Vorhersage der intestinalen Absorption von festen Lösun-
gen mit Soluplus R eingesetzt würden.
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 MICELLES
A. Characterization of Soluplus Rmicelles
Introduction
As described in Chapter 6, the drug transport across Caco-2 cells is dependent on an en-
trapment of the respective drug in micelles formed by Soluplus R. For further investiga-
tions of this behavior the micelle size at different conditions was studied by dynamic light
scattering (DLS). All measurements were performed using a Malvern Zetasizer Nano ZS
(Malvern Instruments GmbH, Herrenberg, Germany).
Analytic ultracentrifugationwasperformedatBASFSE (Dr. WendelWohlleben, Volodymyr
Boyko) on a Beckman XLI/XLA ultracentrifuge with absorption and interference optics at
a rotation speed of 60,000 rpm and a temperature of 23 C.
Temperature effects on micelle size
By increasing temperature the micelle size strongly increases until the lower crystalline
solution temperature (LCST)is reached (Figure A.1). For temperatures above the LCST, the
measured size slightly decreases probably to aggregation of Soluplus R micelles to solid
particles.
Concentration effects on micelle size
Increasing Soluplus R concentrations have no inϐluence on the micellar size at a temper-
ature of 25 C and the size is stable at around 66 nm. At 37 C the micelle size increases
with increasing concentration (Figure A.2). The polydispersity increases which is also ex-
pressed by the appearance of double-peaks in DLS size-intensity plots (Figure A.3). These
double-peaksmight also be an indicator for the formation of rod-like or layered structures.
A beginning aggregation at this point close to the LCST of 40 C is probable.
Effects of osmolarity on micelle size
The osmolarity of a 1%Soluplus R solutionwas changed, by addition of either NaCl or glu-
cose. As shown in Figure A.4, increasing concentrations of NaCl or glucose lead to shifted
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Figure A.1.: Temperature/size plot of Soluplus R micelles solved either in water or Krebs
Ringer buffer pH 7.4 (concentration: 1% (w/w)). Lower crystalline solution
temperature (LCST) is marked by the vertical line.
Figure A.2.: Concentration dependence of Soluplus R micelles at 25 C and 37 C.
114
APPENDIX A. CHARACTERIZATION OF SOLUPLUS R MICELLES
Figure A.3.: DLS size/intensity plot of 1.5% Soluplus R solution (n=3).
A B
Figure A.4.: A: Addition of the ionic additive NaCl leads to shifted temperature/size curves
and reduced LCST B: Addition of the non-ionic additive glucose shifts curves
to lower temperatures and higher micellar sizes. n=3; mean SD
temperature/size plots. For both additives, the curves are shifted to lower temperatures
for increasing concentrations (Figure A.5 A). While for the non-ionic additive glucose the
micelle size at 37 C is slightly increasing, for the ionic additive sodiumchloride themicelle
size at body temperature decreases for hypertonic conditions (Figure A.5 B). As shown
before, the maximal size is located at the LCST, therefore a shift of the LCST to lower tem-
peratures can be assumed for high NaCl concentrations (> 2%).
Effects of drug load onmicelle size
DLS measurements showed no or only slight differences in the micellar size, whether the
micelles were drug loaded or not (Figure A.6).
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A B
Figure A.5.: A: Half-maximal temperatures of Plot A.4 versus osmolarity. B: Micelle size at
37 C is not only dependent on the osmolarity, but also on the used additive.
Figure A.6.: Temperature/size plot of Soluplus R micelles with and without solubilized
drug.
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Figure A.7.: Analytical ultracentrifugation of Soluplus R in H2O. Micelles and free solved
polymer can be observed.
Analytical ultracentrifugation
By the time this work was written only preliminary data of the analytical ultracentrifuga-
tion (AUC) was available. However, also this preliminary data gives us hints for a better
understanding how Soluplus R micelles act in solution.
Analytical ultracentrifugation of pure Soluplus R (1%) offered two forms of the polymer
in solution: First, micelles of a diameter between 20nm and 30nm and second, solved
polymer, probably monomers, at a size of around 3 nm (Figure A.7).
Analytical ultracentrifugation of itraconazole-loadedmicelles showed a changed behavior.
In this experiment, a solid solution containing 15% itraconazole was dissolved to a ϐinal
Soluplus R concentration of 1%. While Soluplus R alone showed a bimodal distribution,
the distribution is trimodal by addition of itraconazole (Figure A.8). By selective UVVIS-
AUC it was possible to distinguish the drug content in the centrifugation plot. According to
this measearuments the drug was only present in the biggest structures. Further analysis
of the AUC plot showed that in this big drug-loaded structures, the ratio between excipient
and API is approximately 1:1.
This ϐirst results from analytical ultracentrifugation are partially contradictorily to those
from the DLS measurements (see above). However, DLS measurements are often tending
for technical reasons to a monomodal distribution and to overestimate bigger structures
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Figure A.8.: Analytical ultracentrifugation of Soluplus R + itraconazole. Speciϐic UV-
Absorption of itraconazole at 267 nm is only present in the biggest structures.
28% of the solids were found in large micelles.
[163]. Therefore, these results prove the existence of micellar-bound drug in a compact
structure. Ongoing experiments will further show how this structures behave at differ-
ent excipient/drug ratios, temperatures and in varying media. This data will help us to a
further understanding of the mechanisms how the binding between drug and Soluplus R
occurs. Also the observed decreased transport across Caco-2 cells as result of this binding
may be further elucidated.
118
APPENDIX B. TEER MEASUREMENTS THROUGHOUT TRANSPORT EXPERIMENTS
B. TEERmeasurements throughout
transport experiments
All measurements of the transepithelial electrical resistance (TEER) in this work were
performed by a so called “chop-stick” electrode (STX-2 electrode, World Precision Instru-
ments, Sarasota, FL, USA). Therefore, the shorter end of this electrode was inserted in the
apical compartment, and the longer end into the basolateral compartment of the Tran-
swell systemwithout contact to the cell monolayer. The electrical resistance was read out
by an electrical Volt-Ohmmeter (EVOM). As shown in Figure B.1, Soluplus R did not affect
the integrity of the cell monolayer, as the TEER values stay constantly on the level of the
untreaten control (KRB buffer).
Soluplus concentration
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Figure B.1.: TEER values after ϐluoresceine sodium transport experiment with varying
Soluplus R concentrations. Expressed as % of the pre-experimental value
(n=3; mean  SD). Absolute TEER values were above 500 
 cm2 before the
experiment (qualiϐication criterium for transport experiments).
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C. HPLC and LC/MS analytics
Introduction
In this appendix the analytical methods for danazol, itraconazole and fenoϐibrate are sum-
marized. HPLC was used for quantiϐication of danazol, fenoϐibrate, fenoϐibric acid and
itraconazole of samples from Caco-2 transport and equilibrium dialysis of the respective
drugs. LC/MSwasused for thequantiϐicationof plasma samples of the animal experiments
(performed at BASF SE).
HPLC
All HPLC analytics were performed on Dionex (Dionex Corporation, Sunnyville, CA, USA)
machines using UV/Vis absorptiometric detection. Reversed phase columns of type Li-
ChroCART 125-4 LiChrospher 100 RP18 (5 µM) (Merck KGaA, Darmstadt, Germany) were
used for separation. Further information is given in Table C.1. Representative chromato-
grams for each substance are shown in Figures C.1–C.4.
Figure C.1.: Representative chromatogramm and calibration curve for danazol HPLC
analytics
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Figure C.2.: Representative HPLC chromatogramm and calibration curve for the active
compound fenoϐibric acid
Figure C.3.: HPLC chromatogrammof fenoϐibrate alone and in combinationwith fenoϐibric
acid. Slight changes in retention time are due to analysis on different HPLC
machines and slight changes in eluent composition
Figure C.4.: Representative chromatogramm and calibration curve for itraconazole HPLC
analytics
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LC/MS
Bioavailability studies using beagle dogs were performed by BASF SE. The below listed
LC/MS methods for drug quantiϐication in plasma samples are summarized as received
from BASF SE.
Danazol
LC/MSmachine ABSciex API 3000
Column Symmetry C18 150 2, 1mm, 5 µm
Eluents A: highly deionized water
B: acetonitrile
Gradient
0min 50% B
10min 100% B
13min 50% B
Flow rate 0.3ml/min
Injection volume 25 µl
Detection by MS was performed by ESI-MS positive ionization in a single reaction mode
(SRM; 160 C; 4000V) with mass transition m/z 338 to 310, 295, and 148. The collision
energy was 20V. Quantiϐication was based on external calibration. The limit of quantiϐica-
tion was 10 ng/ml.
Itraconazole
LC/MSmachine WATERS 2695 Separations Module with
QuattromicroTMmass detector
Column Luna C18 50 2mm, 2.5 µm
Eluents A: highly deionized water, acidiϐied with
formic acid (1ml/l)
B: acetonitrile, acidiϐied with formic acid
(1ml/l)
Gradient
0min 50% B
2min 95% B
5min 95% B
5.1min 50% B
Flow rate 0.3ml/min
Injection volume 10 µl
Detection by MS was performed by ESI-MS negative ionization in a single ion monitoring
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(source temperature 120 C; desolvation temperature 250 C; 3200V). Quantiϐicationwas
based on external calibration. The limit of quantiϐication was 1.3 ng/ml.
Fenoϐibrate/Fenoϐibric acid
Fenoϐibrate only appeared as its active form fenoϐibric acid in animal plasma samples.
Fenoϐibric acid was analyzed by an appropriate BASF-internal LC/MS method.
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APPENDIX D. ABBREVIATIONS
D. Abbreviations
A/D ratio acceptor/donor ratio HPCD hydroxypropyl--cyclodextrin
AB, A to B transport apical to basolateral transport HME hot melt extrusion
ABC ATP binding cassette HPLC high performance liquid chromatography
ADME absorption, distribution, HPMC hydroxypropyl methyl cellulose
metabolism, excretion/elimination ICH International Conference on Harmonisation
ADP adenosine diphosphate itra itraconazole
API active pharmaceutical ingredient IVIVC in-vitro in-vivo correlation
ATP adenosine triphosphate IU international unit
AUC area under the curve KRB Krebs Ringer buffer
AUC analytical ultracentrifugation LADME liberation, absorption, distribution,
BA, B to A transport basolateral to apical transport metabolism, excretion/elimination
BA N--benzoyl-L-arginine LC/MS liquid chromatography/mass spectrometry
BAEE N--benzoyl-L-arginine ethyl ester LCST lower crystalline solution temperature
BCRP breast cancer resistance protein LOD limit of detection
BCS biopharmaceutics classiϐication system LOQ limit of quantiϐication
BSA bovine serum albumine MCT1 monocarboxylate transporter 1
CHO chinese hamster ovary MDCK Madin darby canine kidney
CMC critical micelle concentration MDR1 multidrug resistance protein 1
CysA Cyclosporine A MES 2-(N-morpholino)ethanesulfonic acid
D/A ratio donor/acceptor ratio m.p. melting point
dana danazol MRP multidrug resistance associated protein
DIG digoxin NBF nucleotide binding fold
DLS dynamic light scattering NCE new chemical entity
DMEM Dulbecco’s modiϐied Eagle’s medium NEAA non-essential amino acids
DSC differential scanning calorimetry OATP organic anion transporting peptide
FaSSIF fasted state simulated intestinal ϐluid P-gp P-glycoprotein
FBC fetal bovine serum Papp apparent permeability
FCS fetal calve serum PM physical mixture
FDA US Food and drug administration rH relative humidity
feno fenoϐibrate RHO rhodamine 123
FeSSIF fed state simulated intestinal ϐluid SD standard deviation
GI gastro-intestinal TEER transepithelial electrical resistance
HEPES 4-(2-hydroxyethyl)-1-piperazine- Tg glass transition temperature
ethanesulfonic acid TPGS -tocopheryl polyethylene glycol succinate
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